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ABSTRACT 
 
Pompe disease is a rare inherited metabolic disorder due to the deficiency of the lysosomal enzyme 
alfa glucosidase, with consequent abnormal glycogen accumulation in muscle fibres. The late-onset 
form (LOPD) is characterised by a progressive motor and respiratory impairment. The specific 
enzyme replacement therapy (ERT), has been proved to stabilise muscle functions, but its effect 
after many years of treatment seems to be limited, especially for those patients who are already 
compromised at baseline. Exercise intolerance is one of the first clinical hallmarks affecting LOPD 
patients' quality of life. Functional evaluation of exercise tolerance is a recently tested method to 
assess clinical LOPD outcome. Before the introduction of ERT, the positive effects of diet and 
exercise training had already been demonstrated in LOPD, but the effect of these interventions on 
patients treated with ERT is still debated and poorly known.  
This thesis is articulated into 3 studies, the first investigate the long term (more than 5 years) effects 
of ERT on a cohort of patients with the juvenile form of LOPD. The second investigates the acute 
effects of ERT on the main variables linked to exercise tolerance, dividing patients by clinical 
severity and level of habitual physical activity, and comparing results obtained from exercise 
tolerance test with those from standard six minutes walking test (6MWT). The third study is still 
ongoing, and investigates if a specific program of exercise training, alone or combined to 
hyperproteic diet, can ameliorate exercise tolerance in LOPD patients chronically treated with ERT. 
For patients’ clinical evaluation the following parameters were mainly used: serum muscle enzymes 
(AST, ALT, CPK, LDH ), muscle strength (by dynamometer), motor function (6MWT, Walton 
Scale), neurologic functional tests, pulmonary function tests (standard spirometry, Maximal 
Inspiratory Pressure, Maximal Expiratory Pressure). 
The functional evaluation of exercise tolerance was conducted on a cycle-ergometer and a specific 
exercise protocol adapted to patients was developed. The main variable of exercise tolerance 
assessed were: maximal aerobic power; gas exchange threshold; kinetics of pulmonary gas 
exchange during constant work-rate exercises; skeletal muscle fractional O2 extraction by near-
infrared spectroscopy; heart rate, pulmonary ventilation and gas exchange ratio during constant 
work-rate exercise; rates of perceived exertion; time to exhaustion.  
The results of these studies demonstrate: 1. Patients with the juvenile form of Pompe disease show a 
stabilization of motor and respiratory functions after 5 years of regular treatment with ERT. Patients 
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who started therapy in an asymptomatic phase were still free of symptoms after 6 years of follow 
up, suggesting that ERT is more efficient if started at early stages of the disease. 2. The exercise 
tolerance test is not acutely influenced by ERT, its main utility in clinical practice is in the long 
term follow up of patients, in which it seems to be more sensible than the 6MWT. The habitual 
physical activity seems to improve the exercise tolerance, regardless the disease severity. 3. Aerobic 
exercise training may ameliorate skeletal muscle force, maximal aerobic capacity and peripheral 
oxygen extraction in LOPD patients on chronic ERT treatment. 
 
  
4 
 
GENERAL INTRODUCTION 
 
POMPE DISEASE 
 
Pompe disease, or glycogen storage disease type II, is an inherited metabolic disorder due to the 
deficiency of the enzyme acid alpha glucosidase (GAA), which normally breaks down the glycogen 
inside the lysosomes of various cellular types. Since the GAA is the only way for glycogen 
degradation inside the lysosomes, a GAA deficiency brings to glycogen accumulation inside these 
organelles, especially in muscle fibers of skeletal, respiratory and cardiac muscles. The 
consequence is a progressive invalidating disease [HirschHorn R et al 2001].  
In clinical practice Pompe disease has been differentiated in two main subtypes: the classic infantile 
form, rapidly progressive with cardiac involvement, and the late-onset form, more slowly 
progressive and free from cardiac involvement. But patients can present a wide variability in the 
clinical spectrum, between these extremes [van den Hout HM et al 2003; Hagemans ML et al 
2005]. 
The disease was first described in 1932 by dr J.C. Pompe, who reported a clinical case of a 7 years 
old patient with progressive muscle weakness and hypertrophic cardiomyopathy, with evidence of 
massive glycogen accumulation inside the skeletal muscle cells and the cardiac tissue [Pompe JC 
1932]. 
Pompe disease is considered a rare disorder, with an estimated incidence varying from 1 in 14.000 
to 1 in 300.000 live births, depending on the form, the geographic location and ethnicity. In the 
caucasian population the estimated incidence is 1/138.000 for the infantile form and 1/57.000 for 
the late onset form [Ausems MG et al 1999]. 
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Molecular genetics 
Pompe disease is a genetic disease, inherited in an autosomal recessive manner.  
The gene encoding for the GAA (GAA gene) is located in the long arm of the 17 chromosome 
(17q25.2-q25.3). It contains 20 exons and 19 introns, with a total length of 28 Kb [Tzall S et al 
1991]. 
The acid alpha glucosidase is a lysosomal enzyme, which normally catalyses the hydrolysis of the 
1-4 and 1-6 links of the glucose molecules inside the glycogen, leading the release of the glucose 
subunits. This enzyme works at a pH between 4.0-5.0. The expression of the GAA is present in all 
body cells, but it is prevalent in muscle tissue, especially in the striated muscle [Auricchio F et al 
1968]. 
The cDNA of the GAA codify for a precursor peptide of 952 amino acids, with a molecular mass of 
105.3 kDa, which underwent important structural post-translational modifications. First, in the 
reticular endothelium, the precursor is glycosylated with high mannose olygosaccharides, 
subsequently, in the Golgi apparatus, there is a phosphorylation of the mannose residues forming 6 
phosphate mannose (M6P). In that way there is the formation of an inactive precursor of 110 kDa. 
Then there are two proteolysis at the amino-terminal end, finally forming a protein of 70 and 76 
kDa, which is the active form of the enzyme (with an affinity for glycogen increased of 10 times 
compared to the precursor). The final protein leaves the Golgi complex in a vesicle which delivers 
its content to early/late endosomes and lysosomes, utilizing the M6P receptor. Once inside the late 
endosomes, the receptor-ligand complexes dissociate due to the low pH in these vesicles, and the 
enzyme is delivered to the lysosome, whereas the receptors is recycled back [Wisselaar Ha et al 
1993; Kornfeld et al 1992]. 
Now a day, around 300 mutations and 80 polymorphisms have been identified in the GAA gene, the 
majority are point and private mutations [http://www.pompecenter.nl]. 
In patients with the classical infantile form, there is a wide mutation spectrum, all severe. In this 
group of patients, the most frequent mutation is a deletion: c.525delT, with an allele frequency of 
12% in the Italian population. This mutation causes the deletion of a pair of bases in the exon 2, 
resulting in a premature stop codon. 
The most frequent mutation founded in the late-onset form involves the first intron of the GAA 
gene: c.-32-13T>G. This is a splicing mutation causing a defecting elimination of the exon 2. Since 
a certain amount of correct mRNA is still produced, the residual GAA activity leads to a clinical 
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moderate phenotype (thus, this mutation is not present in the classical infantile form) [Huie Ml et al 
1994]. In a study performed in an Italian cohort of 40 patients with late-onset Pompe disease, the c.-
32-13T > G was confirmed as the most frequent mutation, present as compound heterozygote in 
85% of the patients, with an allele frequency of 42.3%. The c.-32-13T > G was associated with the 
c.2237G > A (p.W746X) in nine of the 40 patients [Montalvo AL et al 2006]. 
Although some genotype/phenotype correlations have been described in Pompe disease, it must be 
pointed out that clinical presentation could be very different even among patients of the same 
family [Montalvo AL et al 2006]. 
 
 
 
 
 
 
 
Figure 1.   GAA gene and  protein structure of GAA 
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Pathophysiology 
In Pompe disease, the metabolic defect consist in the lack of function of the GAA enzyme, which 
works inside the lysosomes breaking down the lysosomal glycogen. This enzymatic defect leads to 
lysosomal glycogen accumulation in cells. Nevertheless, the glycogen accumulation is not the only 
mechanism of cell damage in Pompe disease, recent studies evidenced the key role of different 
pathways such as oxidative stress, mithocondrial dysfunction, accumulation of toxic potentially 
undegradable material and, most importantly, aberrant authofagy, which destroy the normal 
architecture of muscle cells and deeply contribute to muscle damage. 
Authophagy is the natural, regulated, destructive mechanism of the cell that disassembles 
unnecessary or dysfunctional components, allowing the orderly degradation and recycling of 
cellular components. Three authofagic pathways have been described: microautophagy (direct), 
chaperone mediated authophagy, and macroauthophagy, most relevant for Pompe disease, which 
supplies aminoacid and energy sources under starvation by self digestion of cellular component 
[Huang J et al 2007]. Studies performed on Pompe muscle biopsies with the electron microscopy 
evidenced pathological autophagic abnormalities, with increase in the number of authophagosomes 
indicating an upregulation of authophagy and defect in the authophagosome-lysosome fusion. Thus, 
in Pompe disease there is a profound disorder of the intracellular recycling system, which contribute 
to the muscle weakness and to the incomplete response to therapy [Raben N et al 2007].  
Moreover, muscle biopsies of the majority of patients with different forms of Pompe disease 
showed lysosomes containing large irregurarly shaped autofluorence inclusions identify as 
lipofuscin. Gradual intralysosomal accumulation of lipofuscin is characteristic of cellular oxidative 
damage and aging. Since lysosome and authophagy are involved in mitochondrial degradation, the 
reduced degradative capacity of lysosomes due to the progressive deposition of lipofuscin in these 
organelles leads to a decrease in the authophagic turnover of damaged mithocondria, which results 
in increased production of oxygen reactive species, perpetuating the production of lipofuscin. 
Furthermore, intralysosomal accumulation of lipofuscin affects the trafficking of the newly 
sintetised lysosomal enzymes, down regulating more the already impaired degradating capacity of 
lysosomes, in a sort of “vicious circle” [Lim JA et al 2014]. 
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Figure 2.   Primary metabolic defect in cells with Pompe disease. The lack of function of GAA 
brings glycogen accumulation in cells [from Cupler EJ et al 2012]. 
 
 
 
 
 
Figure 3.   Electron microscopy of muscle fibers from a knockout mouse with Pompe disease 
evidencing the presence of autophagic buildup [from Raben N et al 2007]. 
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Clinical Forms 
Pompe disease presents as a spectrum, ranging from the severe classical infantile form to the milder 
late on-set form.  
The infantile onset form can be divided in classical infantile and non classical infantile. The late 
onset form present after the 1 year of life and can be divided in juvenile form and adult form, 
depending on the age at onset [van der Ploeg AT et al 2008]. 
The classical infantile form usually presents within the first months of life with severe hypotonia 
(floppy infant), respiratory insufficiency and cardiomegaly due to hypertrophic cardiomyopathy. 
Other clinical features can be hepatomegaly, enlarged tongue, and lack of the achievement of the 
major motor milestones. If untreated, it leads to death within the first year of life, consequently to 
cardiopulmonary failure or aspiration pneumonia. 
The non classical infantile form present before 2 years of life, has no or mild cardiomyopathy and is 
characterized by progressive hypotonia and motor delay or regression, with variable outcome [van 
den Hout HM et al 2003]. 
The late onset forms are characterized by a slowly progressive disease, usually without cardiac 
involvement.  
The juvenile forms develops in the 1st or 2nd decade of life and are characterized by predominant 
skeletal muscle dysfunction, with motor and respiratory impairment. 
The adult forms develops in the 3rd or 4th decade and affect the trunk and proximal limb muscles, 
mimicking limb girdle muscle dystrophies. The diaphragm muscle is often involved, leading to a 
respiratory insufficiency. 
In the natural history of the late onset forms the myopathy and respiratory insufficiency deteriorate 
gradually, and patients often become dependent on ventilator and wheelchair [Hagemans ML et al 
2005]. 
The major cause of death in adults is respiratory insufficiency. Rarely death occurs after strokes 
related to intracranial aneurysms or artheriopathy do to the accumulation of glycogen in the 
vascular smooth-muscle cells [Laforet et al 2008]. 
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Diagnosis 
The diagnostic process may start from the clinical evaluation, or from a genetic test in case of 
familiar screening, or from the neonatal screening, where available. 
Clinical Suspicious: 
In the classical infantile form the clinical presentation is quite characteristic, and consist in early 
onset (first months of life) of severe hypotonia, with babies having the classical aspect of the floppy 
infant, respiratory distress, abnormal electrocardiogram (short PR interval, high QRS complex 
voltage and arrhythmias) and cardiac imaging (X ray of the thorax or echocardiography) showing 
marked cardiac hypertrophy. Further characteristics may be motor delay or regression, 
hepatomegaly, macroglossia, skeletal abnormalities such as scoliosis, joint restriction, osteopenia 
with fractures, coclear involvement with deafness, and cerebral involvement with delayed 
myelination, anterior horn neurons involvement and aneurisysms. The laboratory blood exams 
usually show increased muscle enzyme: creatine chinase (CK), aspartate aminotransferase (AST), 
alanine aminotranferase (ALT), lactate dehydrogenase [Kishnani PS et al 2006]. 
As regards the late onset forms the clinical manifestations can be subtle, therefore the diagnosis 
may be significantly delayed. 
The signs that should bring a physician to the suspect of a juvenile form is a patient with an age 
between 2 and 18 years presenting with muscular weakness, or motor abnormalities, without a 
cardiac involvement, with possibly recurrent respiratory infections. The blood tests show an 
increase in CK (>2 fold), AST, ALT and LDH.  
Increased CK may occasionally be found in juvenile patients, in the absence of other clinical 
manifestations. In that case the exams should be repeated 3 times, and if consistently high further 
diagnostic evaluation to investigate a possible underling Pompe disease should be performed. 
The main clinical features of the adult forms are the consequences of the skeletal muscle 
involvement and of the respiratory muscle involvement and includes: proximal lower limbs and 
paraspinal muscle weekness, exercise intolerance, back pain, respiratory distress, sleep apnoea, 
exertional dyspnea, recurrent respiratory infections. Respiratory disturbances can cause headache 
and somnolence. In some cases the disease presents suddenly with a severe acute respiratory failure, 
in these cases the prognosis is usually poorer. Again the laboratory tests shows an increase in CK 
(>2 fold), AST, ALT and LDH [Raben N et al 2002]. 
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As regards instrumental exams electromyography and nerve conduction studies are not specific but 
can help in the diagnosis, showing myophatic features. 
When skeletal muscle involvement is prominent, muscle biopsy can be useful, showing acid 
phosphatase positive cytoplasmatic vacuoles and increased glycogen content during periodic acid 
Schiff stain. Nevertheless morphologic changes are variable and some patients may show a 
confounding normal biopsy. This can be explained by the fact that glycogen storage may be 
different in different fibers. 
Thus, the diagnosis of Pompe disease should always be confirmed by enzymatic essays or 
molecular analysis. 
The differential diagnosis should include other muscular disorders such as muscular dystrophies, 
inflammatory myopathies, and other congenital storage disorders such as Danon disease, and 
glycogen storage disease type V [Bembi B et al 2008]. 
 
Figure 4. Muscle involvement in Late onset Pompe disease 
Red: severe; yellow: moderate; green: mild; gray: null or minimal. 
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The enzyme assay 
Enzyme GAA activity can be detected on different tissues: skeletal muscle (from muscle biopsy), 
skin fibroblast (from skin biopsy) or leucocytes (from peripheral blood samples). A pathological 
GAA level in any of these tissues is sufficient for the diagnosis of Pompe disease. 
GAA enzyme activity is tested at an acid pH (3.7-4.4) using natural or synthetic substrates. 
In the classic infantile form the GAA residual activity is usually undetectable (less than 1% of 
normal controls, in skin fibroblasts), while in the late onset forms it is usually reduced, but 
detectable (4-40% of normal controls, in skin fibroblasts) [Raben N et al 2002]. 
The molecular analysis 
The analysis of the GAA gene is important to confirm the diagnosis of Pompe disease, especially in 
patients with inconclusive clinical and biochemical studies. The detection of the patient’s specific 
mutation also allow a genetic test in eventual siblings and other close relatives. Furthermore it is 
important to perform molecular analysis because some genotype-phenotype correlation are known 
(see the molecular genetics above section) [Kroos M et al 2008].  
Neonatal screening 
In some country, but not in Italy, the neonatal screening for Pompe disease is recently became 
available. It consist in detecting enzyme assay on dried blood spot (DBS) on filter paper. If the 
results of the DBS indicates a severe reduction of GAA activity, the diagnosis should be confirmed 
by the gold standard tests (enzyme assay on leucocytes or fibroblast and genetic test). The aim of 
the neonatal screening is to early identify patients with the classical infantile form, to be able to start 
therapy as soon as possible. Unfortunately the neonatal screening deals with ethical issues, since it 
can identify also the late-onset forms, which can be asymptomatic until the second, four or six 
decade of life [Umapathysivan K et al. 2001]. 
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Enzyme replacement therapy 
The rationale for the enzyme replacement therapy (ERT) for lysosomal disorders, is to substitute the 
lacking endogenous enzyme injecting a recombinant enzyme which resemble the endogenous one, 
utilizing the ability of cells to internalize lysosomal enzymes through surface receptors. 
The enzyme replacement therapy for Pompe disease consist in a recombinant human GAA 
produced from Chinese Hamster Ovary (CHO) cells (rhGAA; alglucosidase alpha, Myozyme®, 
Genzyme corporation, Framingham, MA). rhGAA is a protein of 110kDa, which is homologous to 
the endogenous GAA precursor, and contains M6P groups that enable the rhGAA to bind the M6P 
receptor on the cell surface and being internalized. Once inside the cells, the rhGAA, like the 
endogenous precursor, is clivated to the fully mature forms of 76 and 70 kDa. 
The drug received broad label marketing approval in Europe in 2006, and lately in the US. This was 
the first specific approved therapy for Pompe disease, and is still the only commercially available 
treatment for Pompe disease worldwide.  
The standard dosage approved for the drug is 20 mg/kg e.v. every two weeks, which is significantly 
higher compared to other ERT for other lysosomal storage disorders. The time of infusion is around 
4 hours, if the drug is well tolerated. 
Since the rhGAA is a protein, the main risk for the patient on treatment is to develop an immune 
reaction, which could be life-threatening especially for those patient with null endogenous GAA 
production (classic infantile forms called CRIM negative). Allergic reactions IgE mediated, ranging 
from mild urticaria to anaphylactic reaction, may also occur in the late-onset forms. Furthermore 
inhibitory IgG antibodies, which limits the efficacy of the drug, may be detected after many years of 
treatment. If the patient doesn’t develop an antibody reaction against the recombinant protein, the 
side effects are usually mild and include fever, cough, nausea and abdominal pain. Even thought 
rhGAA is generally well tolerate, the ERT implies frequent intravenous infusions all lifelong, which 
can comprehensively compromise patient’s quality of life [Angelini et al 2012]. 
As regards effectiveness of the drug, the initial assumption was that early treatment, initiated before 
irreversible compromising of muscle fibers, would reverse the glycogen accumulation and cure the 
disease. Unfortunately the clinical experience showed that while the cardiac muscle responded 
extremely well to therapy, the skeletal muscle did not. In fact both patients with the childhood and 
adult forms experience limited clinical benefit on the motor and respiratory symtomps, with partial 
functional improvement evidenced especially in the first years of treatment, and disease progression 
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thereafter [Kishnani PS et al 2007; Strothotte S et al 2010; Bembi B et al 2010]. The reason is 
probably in the poor uptake of the drug by the peripheral muscles, likely due to the low number of 
M6P receptors present on the plasma membrane of skeletal muscle cells. 
Since the cardiac hypertrophy well responds to therapy, prolonging patients’ survival, the indication 
is to start therapy as soon as possible in the classical infantile forms [Nicolino M et al 2009], while 
the timing of initiation of the therapy in the late onset forms is still debated. 
The limitation of the current available therapy stimulate research on more effective treatments. 
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Follow up 
A patient with Pompe disease should be followed up by a multidisciplinary team including a 
metabolic physician, a neurologist, a pneumologist, a physiotherapist and specialized nurses with 
experience in enzyme replacement therapy. 
The regular follow up at the Regional Coordinator Center of Rare diseases of the Academic 
Hospital of Udine includes periodic visits (every 6 or 12 months, depending on the clinical severity 
of patients) with the following evaluations: 
? general evaluation 
? complete neurological evaluation 
? blood exams, including blood count, renal and liver function, protein profile, glycemia, 
lipid profile and muscle enzymes: CK, LDH, AST and ALT 
? electrocardiogram  
? pulmonary function tests (spirometry with evaluation of the Forced Vital Capacity-FVC 
in sitting and supine positions, maximal inspiratory pressure -MIP, maximal exipiratory 
pressure MEP) 
? 6 minutes walking test (6MWT) 
? muscle imaging (every one or two years) 
? DEXA body scan (every two years), to detect body composition 
Other exams are performed depending on patient’s clinical status, and include polisomnography to 
detect eventual nocturnal oxygen desaturations, and blood gas analysis (for those with respiratory 
insufficiency). 
The 6MWT is a simple and reproducible test, which measures the distance a patient is able to walk 
over a total of 6 minutes on a flat surface. Patients are asked to walk as far as possible, but the 
individual is allowed to rest if needed. The principal parameters measured with the 6MWT are the 
total distance walked in meters, the peripheral oxygen saturation at baseline and end of the test, the 
heart rate, and the scoring at the BORG scale, which consist in two types of scores indicating, from 
0 to 10, the subjective level of respiratory and muscle fatigue. The 6MWT is widely used in clinical 
practice to assess exercise capacity, since it does not require special equipments. Nevertheless this 
test has several limits, not providing information of function of the different organs and systems 
involved in exercise, or about its limiting factors [ATS statement 2002]. 
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Muscle imaging usually consist in magnetic resonance (MRI) of the trunk and the thigh muscles. 
The imaging may evidence muscle abnormalities consisting in fatty degeneration and decreased 
muscle trophism, typically with a symmetric involvement. On MRI the fatty degeneration is seen as 
hyperintensity on T1-weighted images (figure 5) [Bembi et al 2008].  
An extensive MRI study on patients with late onset Pompe disease have shown that there is a 
correlation between imaging findings and clinical severity. The adductor magnus, 
semimembranosus and semitendinosus muscles are involved in the initial stadium of the disease. 
Lately, the long head of the biceps femoris, the vastus intermedius, vastus medialis and, to a lesser 
degree, the vastus lateralis are involved with selective sparing of the short head of the biceps 
femoris, the sartorius, rectus, gracilis, and of the peripheral portion of the vastus lateralis. 
Repeating MRI imaging every 1 or 2 years is therefore useful in evaluating disease progression and 
the treatment response. 
MRI could also be useful in the initial differential diagnosis, in fact unless some feature of the MRI 
imaging in Pompe disease are in common with other myophaties, there are two patterns that are 
characteristic of Pompe disease: the selective sparing of the short head of the biceps, despite the 
severe involvement of the long head, and the relative sparing of the tensor fasciae latae, despite the 
severe involvement of the other pelvic muscles [Pichiecchio A et al 2004]. 
 
 
 
Figure 5.   Magnetic resonance imaging of the thigh showing two stages of muscle fatty infiltration 
(moderate left, severe right), seen as hyperintensity on T1-weighted axial images, in two 
patients with late onset Pompe disease [from Bembi et al. 2008]. 
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EXERCISE PHYSIOLOGY: PARAMETERS RELATED TO EXERCISE TOLERANCE  
 
Aerobic exercises, such as running or cycling, require a strict integration of multiple systems 
of the body, including the respiratory, cardiovascular, and locomotor systems. During physical 
exercise, adequate interactions among these systems are required to transport an adequate amount of 
oxygen and nutrients to the exercising muscles as well as to remove the metabolically produced 
carbon dioxide (CO2) from the exercising muscles, to maintain homeostasis. Each of these systems 
plays an important role in exercise tolerance. The respiratory system is a ventilatory pump, moving 
oxygen from the atmosphere to the alveoli and carbon dioxide from the alveoli to the atmosphere. It 
must also provide an effective means of exchanging oxygen and carbon dioxide across the thin 
alveolar walls. The cardiovascular system is responsible for pumping oxygenated blood to the 
exercising muscles as well as returning oxygen-poor and carbon dioxide-rich blood to the 
gasexchanging surfaces of the lungs. The locomotor system, and particularly the muscles, must 
extract oxygen from the blood, generate adenosine triphosphate (ATP) in the mitochondria, and 
contract with force sufficient to support the intended activity. These three systems do not work 
independently, but in a highly coordinated manner. The most significant interdependence is the 
delivery of oxygen to the working muscles. The lungs must efficiently oxygenate blood returning 
from the venous system, and the left heart must then distribute this oxygenated blood to skeletal, 
cardiac, and respiratory muscles in proportion to the amount of work being done by the individual 
muscles. All of this coordination must occur in proportion to the amount of work being performed, 
whether it is mild, moderate, or extreme exercise.  
Pathology in any of these important systems can lead to limitations in an individual’s exercise 
tolerance. In patients with cardiomyopathy, for example, delivery of oxygen to the exercising 
muscles is insufficient to support mitochondrial ATP generation and, as a result, muscle 
contraction. Similarly, in patients with severe chronic obstructive pulmonary disease, altered 
respiratory system mechanics impair ventilation and the patient cannot eliminate CO2 being 
produced in the exercising muscles. As described above, patients with late onset Pompe disease 
may have both the respiratory and the locomotor system involved, with a double component for the 
exercise tolerance impairment. 
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VO2max 
VO2max is the maximal capacity of the pulmonary and cardiovascular system to take up and 
transport oxygen to the exercising muscles and of the exercising muscles to extract and utilize 
oxygen from the blood during progressive exercise. It is one of the most useful parameters to assess 
an individual’s capacity to perform sustained aerobic exercise, describing how much oxygen is 
being used by the tissues per minute. 
VO2max is the product of the maximal cardiac output and the maximal arteriovenous oxygen 
difference (Fick equation): 
 
 
where Q indicates the cardiac output, CaO2 indicates arterial oxygen content, and CvO2 indicates 
the mixed venous oxygen content. Rearranging this equation we see that: 
 
 
This tells us that oxygen consumption is a function of cardiac output and the arteriovenous oxygen 
content difference. 
Recall that: 
 
And 
 
where Hb = hemoglobin concentration, PaO2 = partial pressure of oxygen in arterial blood, PvO2 = 
partial pressure of oxygen in mixed venous blood, SaO2 = arterial oxygen saturation, and SvO2 = 
mixed venous oxygen saturation. Oxygen consumption is therefore dependent on the hemoglobin 
concentration, the arterial partial pressure and saturation of oxygen (reflecting the adequacy of the 
ventilatory pump and gas exchange), and the mixed venous saturation and partial pressure of 
oxygen (reflecting the ability of the tissues to extract and utilize oxygen).  
Therefore, VO2max provides information about many of the systems that are necessary to generate 
sustained, vigorous exercise; the higher the VO2max is, the more effective are all of these systems 
at performing their tasks and the greater is the person’s exercise capacity. Maximum oxygen 
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consumption will vary from individual to individual. Whereas the VO2max for an average 30-year-
old person might be 35–40 ml/kg/minute, an elite cyclist or cross-country skier might have a 
VO2max of 85 ml/kg/minute. Patients with a cardiomyopathy, on the other hand, may have a 
VO2max as low as 15 ml/kg/minute or less, severely limiting the capacity to perform normal 
activities of daily living. Maximum oxygen consumption declines with age, although that decline 
may be substantially delayed in physically active subjects. 
 
 
Anaerobic threshold 
During incremental exercise, ventilation increases to deliver oxygen to the alveoli and eliminate 
CO2. The anaerobic (or ventilator) threshold is the point in which the linear increase of ventilation 
in relation to workload changes its slope. The anaerobic threshold is related to the point at which 
anaerobic metabolism increases in exercising muscles to sustain work when aerobic metabolic 
capacity can no longer meet the physiologic demands, and the body shifts to anaerobic metabolism 
as an additional source of energy. The determination of the anaerobic threshold is a noninvasive, 
reliable, and reproducible diagnostic/prognostic marker that is based on ventilatory dynamics as 
exercise intensity progresses. In healthy untrained subjects the anaerobic threshold usually occurs at 
approximately 45% to 65% of peak VO2, and at a relatively lower percentage of peak VO2 among 
subjects with a reduced exercise capacity. The anaerobic threshold provides information at a 
submaximal level of exercise intensity, therefore it does not require a physiologically maximal 
exercise effort). Indeed, it is useful as a parameter on which to base an exercise prescription for 
patients with an maximal exercise performance, exercise intolerance. 
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O2 cost of exercise 
In general, there is a linear relationship between increasing VO2 and the work rate (watts) achieved. 
The slope of this relationship reflects the ability of exercising muscle to extract O2 and to 
aerobically generate ATP. In general, a reduction (10 mL/min/w) throughout the exercise test or an 
acute flattening at a given point during exercise in the ∆VO2/∆WR relationship suggests the 
possibility of a problem in O2 transport. General reductions may be seen in heart and lung disease, 
and disease in peripheral arterial function and/or mitochondrial myopathy, in which there are 
alterations in the cellular pathways involved in O2 utilization. Furthermore, a pattern of initial rise 
of the ∆VO2/∆WR during exercise followed by abrupt flattening may reflect the onset of ischemia-
induced left ventricular dysfunction in patients with coronary heart disease. Because consistent and 
accurate quantification of workload during treadmill testing is complicated by underlying variability 
during treadmill protocols (eg, body weight and handrail holding), assessment of the ∆VO2/∆WR 
relationship is typically confined to exercise tests using a cycle ergometer. 
[Wasserman K et al 2005]. 
 
 
VO2 Kinetics 
The study of VO2 kinetics is the study of the dynamic VO2 response to exercise and its subsequent 
recovery. When starting a movement or a dynamic exercise, such as cycling or running, the 
energetic requirements of the contracting muscles increase immediately with the first contraction in 
what is called a ‘square-wave’ fashion. Regardless the term “squere-wave”, the response 
demonstrates considerable inertia and, depending on the health or fitness of the individual and the 
exercise intensity, may take from 2 to 15 or more minutes to achieve the steady-state values.  
In more details, at the onset of constant workrate exercise, there are 3 subsequent phases:  
Phase I: an early rapid increase of VO2, that typically start within the first breath.  
Phase II: a rapid exponential increase of VO2  
Phase III: steady-state 
Phase I represents the O2 exchange associated with the initial elevation of cardiac output, and thus 
pulmonary blood flow. Phase II reflects the arrival at the lung of venous blood draining the 
exercising muscles. Consequently, the pulmonary kinetics in Phase II widely reflects the kinetics of 
O2 consumption in the exercising muscles, although there is a temporal gap between events at the 
muscle and those recorded at the lung. For moderate intensity exercise, the onset of Phase III 
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corresponds to the point at which cardiac output plateaus and venous O2 content reach their nadir. 
At higher exercise intensities, the attainment of a steady state might be delayed or absent.  
In the transition from rest, or unloaded exercise, to a work rate with a requirement below the 
anaerobic threshold, the vertical distance between the actual at a given moment and that required in 
the steady state represents the energy requirement that must be met from energy stores within the 
muscle. These stores consist principally of energy released through phosphocreatine hydrolysis and 
anaerobic glycolysis, with a small contribution from O2 stores (myoglobin, venous blood). The 
total O2 equivalent of that amount of energy is termed the O2 deficit. Thus, for a given VO2 the 
faster is the response, the smaller is the O2 deficit that will be incurred. In contrast, extremely unfit 
or unhealthy individuals will have a very slow response and will incur a high O2 deficit and thus a 
greater degree of intracellular perturbation (increased lactic acid, decreased phosphocreatine). Slow 
kinetics mandate a greater depletion of intramuscular phosphocreatine, and a greater rate of 
glycogenolysis leading to greater accumulation of lactate and protons and a greater utilization of the 
limited intramuscular glycogen reserves, all factors which predispose to a reduced exercise 
tolerance [Grassi B et al 1996]. 
 
 
 
 
 
Figure 6.   PhaseI, II and III of VO2 kinetic. Actual breath-by-breath alveolar VO2 response across 
the transient from unloaded cycling to a moderate work rate of a representative subject 
[data from Grassi B et al 1996]. 
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Skeletal muscle fractional oxygen extraction 
The fractional peripheral oxygen extraction indicates the balance between O2 delivery and muscle 
O2 consumption, and can be detected utilizing an instrument called Near Infrared Spectroscopy 
(NIRS). This is a non invasive toll used since 1977 in experiments investigating muscle oxidative 
metabolism in pathophysiology.  
The physical principles of NIRS is based on the absorption of light NIR by hemoglobin in small 
arterioles, capillaries and venules. The instrument’s light (700–1000 nm) penetrates skin, 
subcutaneous fat/skull, and underlying muscle, and is either absorbed or scattered within the tissue. 
Based on the Beer-Lambert Law, photons migrate successfully through tissue regions with the least 
absorbance. In the smallest vessels, minimal light absorption allows for multiple complete passage 
of photons along their path through tissue and therefore changes in chromophore concentrations can 
be detected from the light absorption. In contrast, light emitted into larger vessels (arteries and 
veins) is almost completely absorbed since the molar quantity of blood is so comparatively large. 
The degree of attenuation of NIR light in tissue is due to 3 factors:  
1) O2-dependent absorption from chromophores of variable concentration (hemoglobin Hb, 
myoglobin Mb), and cytochrome oxidase;  
2) absorption from chromophores of fixed concentration (skin melanine) 
3) light scattering.  
Thus, the oxygen saturation of the investigated tissue can be estimated. 
The instrument provides separate measurements of changes in deoxygenated Hb and Mb 
concentrations, as well as oxygenated Hb and Mb concentrations. The fractional peripheral oxygen 
extraction can be calculated as concentration changes of deoxygenated Hb+Mb 
(∆[deoxy(Hb+Mb)]). This parameter, with respect to an initial value arbitrary set equal to zero, is 
considered a peripheral oxygenation index since it is relatively intensive to changes in blood 
volume [Grassi B et al 2007]. 
Today, NIRS is extensively utilized to study circulatory and muscle metabolic pathologies in 
several situations. Distinct abnormalities in tissue oxygenation have been detected with NIRS in 
patients with peripheral vascular disease [McCully KK et al 1994]. Pronounced muscle O2 
desaturation during exercise and delayed recovery after exercise have been observed in heart failure 
patients with impaired cardiac output and muscle blood flow [Hanada A et al 2000]. Moreover, 
abnormalities in muscle oxidative metabolism have been detected with NIRS in patients with 
metabolic myopathies such as Mc Ardle disease and mitochondrial disorders [Grassi B et al 2007]. 
Finally, in patients with Pompe disease oxygen changes in a superficial portion of the vastus 
lateralis muscle were evaluated during exercise, both before starting the enzyme replacement 
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therapy and after one year of treatment, demonstrating an increase in ∆[deoxy(Hb+Mb)] after 
therapy, index of a potential better peripheral oxygenation, however this data did not reach the 
statistical significance (but it must be considered that only 4 patients were included in this study) 
[Marzorati et al 2012]. 
 
 
 
 
Figure 7.   Physical functioning of NIRS. From Mc Cully and Hamaoka 2000. 
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AIM OF THE THESIS 
 
My PhD work derives from a collaboration between the Regional Coordinator Centre for Rare 
Diseases of the Academic Hospital of Udine, and the laboratory of Exercise Physiology of the 
Department of Biomedical Sciences and Technologies of the University of Udine, and it is focused 
on late onset Pompe disease.  
 
The Centre for Rare Diseases of Udine has the peculiarity of following a great number of patients 
with Pompe disease as for a single centre (22 patients), with a longtime experience with the enzyme 
replacement therapy (ERT) for this disease, as many patients, at present, have been treated for more 
than 5 years.  
In literature, reports evaluating the long term (>3 years) effects of ERT in the late onset forms of 
Pompe disease (LOPD), and particularly in juvenile forms, are still limited. 
As for clinical experience of the above Centre, there seems to be two categories of patients with 
LOPD: those who were diagnosed at very early stages of the disease, who started therapy having 
poor symptoms, who respond well to ERT, and those who were diagnosed at later stages, in which 
the therapy usually shows a positive effect within the first years of treatment, and then the disease 
may stabilize or even decline.  
 
The laboratory of Human Physiology of Udine as an extensive experience in the functional 
evaluation of exercise tolerance in physiological and pathological conditions (Grassi B et al 2007, 
Grassi B et al 2009, Salvadego D et al 2010, Salvadego D et al 2011). Preliminary collaborative 
studies with the Neuromuscular Unit of the I.R.C.C.S Carlo Besta, conducted in a small number of 
patients with late onset Pompe disease (LOPD), have demonstrated the positive effect of ERT on 
exercise tolerance (Marzorati et al 2012).  
Exercise functional tests were utilized in this thesis as a new toll to assess clinical outcome in 
LOPD patients. 
 
Since ERT seems to have a limited effect in LOPD patients, new treatment strategies should be 
found in association to this therapy. Our proposal is that a personalized exercise training and a 
hyperproteic diet could improve clinical outcome in LOPD patients long term treated with ERT. 
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This thesis is articulated in 3 studies with the following objectives: 
1) describe the clinical follow up of patients with the juvenile form of the disease long term 
treated with ERT  
2) assess if ERT may have an acute effect on the main physiological and biochemical variables 
associated to exercise tolerance 
3) evaluate if a specific program of exercise training, alone or combined to a specific diet, can 
ameliorate exercise tolerance and muscle function in LOPD patients long term treated with 
ERT. 
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Abstract 
Glycogenosis type II, a genetic muscle-wasting disorder, results in a spectrum of clinical 
phenotypes. Enzyme replacement therapy is effective in the infantile form of the disease, while little 
is known about its effectiveness in lateonset disease, especially in juvenile patients. The purpose of 
this retrospective cohort study was to assess the long-term effects of enzyme replacement therapy 
(ERT) in juvenile glycogenosis type II (GSDII). Eight Italian juvenile GSDII patients, receiving 
biweekly infusions of 20 mg/kg recombinant human α-glucosidase for at least 72 months, were 
enrolled (median age at therapy start was 11.8 years). Six-minute walk test (6MWT) and forced 
vital capacity (FVC), measured in upright position, were chosen as the principal outcome measures. 
Global motor disability (modified Walton scale (WS)), muscle enzymes levels [creatine 
phosphokinase (CK), lactate dehydrogenase (LDH), aspartate transaminase (AST), alanine 
transaminase (ALT)] and body mass index (BMI) were also analysed both at baseline (therapy start) 
and annually afterwards. At baseline, most patients (six out of eight) did not show muscle function 
impairment (WS≤2). The performance at 6MWT showed a slight improvement during follow-up as 
well as FVC. Muscle enzymes levels. showed a clear decrease after the 1st year of treatment while 
remained stable afterwards. An overall decrease in BMI was also observed during follow-up, 
although at the individual level, trends were variable. Conclusion: ERT is effective in stabilising 
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both motor and lung functions in juvenile patients with GSDII, possibly slowing down the rate of 
disease progression. Randomised controlled trials are needed to understand whether early treatment 
allows juvenile patients to reach adulthood with a more beneficial residual muscular function than 
untreated patients. 
 
 
Keywords Enzyme replacement therapy . Glycogen storage disease type II . Pulmonary function . 
Exercise tolerance 
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GSDII Glycogenosis type II 
GAA Acid α-glucosidase 
LOTS Late-onset treatment study 
FVC Forced vital capacity 
6MWT Six-minute walk test 
CK Creatine phosphokinase 
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Introduction 
Glycogenosis type II (GSDII; OMIM 232300) is a rare autosomal recessive myopathy caused by the 
deficiency of the lysosomal enzyme acid α-glucosidase (GAA), which is involved in glycogen 
metabolism [10, 14]. As a result, glycogen accumulates in lysosomes of several cell types, 
particularly in skeletal muscle fibres. The storage leads to a progressive disarrangement of tissue 
architecture and, consequently, to muscular atrophy and loss of function. 
Diagnosis of GSDII is a two-step process, the first being the formulation of a clinical suspicion 
while the second the 
measurement of GAA activity in peripheral blood cells, cultured fibroblasts or muscle biopsies [7]. 
If GAA activity is absent or deficient, diagnosis is confirmed. The molecular analysis of the GAA 
gene is also recommended, particularly 
in patients whose clinical, morphologic and biochemical features are inconclusive [2, 7, 37], and 
plays an important role in genetic counselling. Moreover, it could be useful to predict the 
development of antibodies to exogenous enzyme, thus identifying children at risk for a poor 
response to enzyme replacement therapy (ERT) [6]. GSDII encompasses a broad spectrum of 
clinical phenotypes, according to age at onset, severity and organ involvement [7, 22]. Nevertheless, 
patients are usually classified as having the infantile (classic and non-classic forms) or the lateonset 
form(juvenile or adult). In the classical infantile disease, the main clinical features are 
cardiomyopathy and muscular hypotonia, rapidly leading to respiratory failure and death within the 
1st year of life, if untreated [16, 21, 29], while the non-classic infantile form is characterised by a 
slower progressive cardiac and pulmonary involvement that generally leads to death during later 
infancy and early childhood [7, 24]. In late-onset GSDII the rate of disease progression is slower, 
cardiomyopathy is usually absent, and the prevalent manifestations involve both skeletal and 
respiratory muscles, causing a progressive limb-girdle myopathy and a variable degree of 
respiratory impairment [12, 19, 36, 38]. Most of the untreated late-onset patients become 
wheelchair and ventilator dependent, and respiratory failure represents the leading cause of death 
[12, 13, 36]. Until the late 1990s, no specific therapies were available for patients affected by 
GSDII, other than supportive care [23]. In 2006, ERT using recombinant human GAAwas 
introduced and approved for all GSDII patients, on the basis of open-label studies showing 
improvements in survival, cardiac function 
and motor outcomes in the classic infantile form [1, 15, 17, 30, 31]. So far, studies on the 
effectiveness of ERT in late-onset phenotypes [3, 8, 25, 27, 28, 33, 34] demonstrate positive but 
variable long-term effects. The late-onset treatment study (LOTS) [34] and the observational studies 
published by Angelini [3] and Strothotte [25] provided evidence on ERT clinical effectiveness in 
29 
 
improving functional exercise capacity and stabilising lung volumes over 18-, 12- and 36-month 
periods, respectively. However, much uncertainty still exists over the use of ERT in the paediatric 
clinical practice. In particular, the long-term effects on juvenile GSDII were not much studied so far 
[8, 28], and the correct timing for treatment start is still controversial. Focusing on juvenile GSDII 
patients, the purpose of this retrospective cohort study was to critically evaluate the long-term 
effects of ERT on muscle enzymes levels, motor performance and respiratory function over a long-
term intravenous treatment (up to 7 years of follow-up). 
 
 
Patients and methods 
retrospective cohort study was conducted in 2013 on a group of eight Italian juvenile GSDII 
patients receiving biweekly 
infusions of 20 mg/kg recombinant human α- glucosidase and followed-up at the Regional 
Coordinator Centre for Rare Diseases, University Hospital “Santa Maria della Misericordia”, Udine. 
The study was approved by the local ethics committee, and patients were enrolled after informed 
consent was obtained from them or their parents. To be included in the study, patients needed to 
have a confirmed diagnosis of GSDII, defined as presenting with deficient GAA enzyme activity 
and/or GAA gene pathogenic mutations. GAA activity was measured in lymphocytes, cultured skin 
fibroblasts or muscle biopsies and was reported as a percentage of the activity recorded in healthy 
controls. A trained paediatrician reviewed all clinical documentations and gathered data on 
pretreatment demographic and clinical history (age at onset, age and disease duration at first 
infusion, use of ambulation devices, need for respiratory support). Information on height, weight, 
muscle enzymes [creatine phosphokinase (CK), lactate dehydrogenase (LDH), alanine transaminase 
(ALT), aspartate transaminase (AST)], sixminute walk test (6MWT), forced vital capacity (FVC) 
and global motor disability during follow-up was collected as well. All parameters were evaluated 
at baseline (T0) and annually afterwards. Body mass index (BMI) was calculated with the standard 
formula [Weight (in kilogrammes)]/[Height in metres)×Height (in metres)], and the corresponding 
Z scores were computed using age- and gender-specific paediatric 
reference values [18]. Six-minute walk test was performed according to the American Thoracic 
Society guidelines [4]. Patients rated their dyspnoea and overall fatigue at baseline and at the end of 
the exercise using the Borg scale [9]. The maximum distance walked was recorded in metres, while 
Z scores were computed using paediatric age- and genderspecific reference values [11]. Pulmonary 
function tests were performed in the upright position, according to current guidelines [20]. Forced 
vital capacity was expressed as a percentage of the predicted value (FVC); the maximum value of 
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three reproducible measurements was used for analysis. Global motor disability was assessed 
through the modified Walton scale (WS; from 0=normal to 7=wheelchair bound) [23, 35]. Data 
were analysed, and graphics were plotted using the statistical package Stata (Stata Statistical 
Software: Release 11.0, 2009. StataCorp LP, College Station, TX, USA). 
 
 
Results 
Eight unrelated juvenile GSDII patients (five males and three females, born between 1991 and 
1999) were enrolled in March 2013. Seven of them were already included in a study on late-onset 
GSDII published in 2010 [8]. Their characteristics at baseline (therapy start) are reported in Tables 
1 and 2. In six patients, the first sign of disease was a CK increase, incidentally observed when a 
blood test was performed for different reasons (e.g. after detection of increased AST and ALT 
during a gastroenteritis), while the clinical onset was characterised by walking abnormalities for 
patient (Pt) 2 and by difficulty in climbing stairs for Pt 3. In all patients, the diagnosis was made 
within 1 year from clinical onset. The GAA enzyme activity at diagnosis ranged between 3 and 10.6 
% of normal values. All patients showed the splicing mutation c-32-13 T>Gon one allele; 
differentmutations were found in the second allele in five patients, while the second mutation 
remained unknown in three. However, in two of them, GAA mRNA analysis showed that the 
second allele was not expressed, suggesting that the unknown allele may harbour an unidentified 
mutation in the non-coding regions of the GAA gene that prevent the formation of a stable mRNA. 
Most patients (n=6) started being treated shortly after the availability of ERT as a treatment for all 
GSDII forms, while two (Pts 6 and 7) started therapy after a couple of years. Overall, the age at 
therapy start ranged from 7.2 to 15 years. At therapy start, all patients showed a pathological 
elevation of CK (median 914 UI/L; range 366–1305), LDH (median 813 UI/L; range 520–1,561), 
ALT (median 120 UI/L; range 83–322) and AST (median 132 UI/L; range 79–283). Six patients did 
not show a significant muscle function impairment at baseline (WS scores of ≤2), while two (Pts 2 
and 4) showed worse WS scores (2.5 and 7, respectively), one of them (Pt 2) already being 
wheelchair bound. The performance at 6MWT was variable, with a Z score ranging between −11.41 
and 0.28. Finally, three patients had a decreased pulmonary function (restrictive spirometry pattern). 
Among them, patients 2 and 4 showed a severe impairment (FVC of <40 % predicted) and already 
required a ventilatory support. Data on a 6-year follow-up were available for all patients except one 
(Pt 6), who started therapy at the end of 2008 and whose length of follow-up was 4 years. This 
patient developed a brain tumour (pinealoblastoma) in 2012, and his follow-up visit was delayed 
due to surgery and hospitalisation. Patients 2 and 3 have been followed-up for 7 years. One patient 
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developed an allergic reaction (skin rash) following the second infusion. This led him to be 
pretreated with intravenous antihistamine drugs before the following infusions, without further 
problems. No adverse effects were reported in all the other patients throughout the entire follow-up 
period. 
 
During the follow-up, muscle enzymes showed a sharp decrease after 1–2 years from therapy start 
and a stabilisation 
afterwards (Fig. 1). However, CK levels decreased to normal values (expressed as inferior to 170 
UI/L) only in one patient (Pt 7). Global motor disability (modified Walton scale) remained 
unchanged in all patients. When the performance at 6MWT was examined, two groups (Pts 2 and 4 
vs others) were identified, according to disease severity. A slight improvement was clear in both, 
irrespective of their performance at therapy start (Fig. 2), although only in three patients that Z 
scores were normal at the end of follow-up. When the respiratory and muscular fatigue experienced 
after the test was analysed (Borg scale), an improvement was observed at T5 (5 years after ERT 
start) in five patients (Table 2). The same two groups could be identified when the FVC was studied 
as well. In both, a similar trend was seen, patients being quite stable in time, irrespective of their 
baseline pulmonary function (Table 2, Fig. 3). However, in Pts 2 and 4, a gradual reduction of 
ventilatory support was possible after therapy start. This led Pt 4 to stop non-invasive ventilation 
after 2 years, although starting it again 4 years later due to a moderate hypercapnia (pCO2 52 
mmHg). Finally, BMI Z score remained negative or decreased to negative values in most patients 
(six out of eight) (Fig. 4). 
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Table 2. Pulmonary function, exercise capacity and global motor disability at baseline (therapy 
start) and after 5 years of treatment. 
FVC% forced vital capacity expressed as a percentage of the predicted value, T0 ERT start, T5 5 
years after ERT start. 
a Tacheostomized at T0 
b
 Four years after ERT start 
c
 Six-minute walk test was stopped after 1 min and 30 s 
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Fig. 1 Muscle enzymes levels from baseline (therapy start) to the end of follow-up. CK creatine 
phosphokinase, LDH lactate dehydrogenase, AST aspartate phosphatase, ALTalanine 
aminotransferase. 
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Fig. 2 Six-minute walk test (6MWT) Z score from baseline (therapy start) to the end of follow-up 
(individual curves and linear fitted values). 
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Fig. 3 Forced vital capacity (FVC) from baseline (therapy start) to the end of follow-up (individual 
curves and linear fitted values). FVC values are expressed as percentage predicted for height, age 
and gender using standard reference values. 
 
 
 
 
 
Fig. 4 Body mass index (BMI) Z score from baseline (therapy start) to the end of follow-up 
(individual curves and linear fitted values). 
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Discussion 
 
It is well known that ERT is effective in infants with GSDII [1, 15, 17, 30, 31], while experience in 
late-onset disease is still limited, particularly in juvenile patients [8, 28]. However, due to the 
differences in the clinicalmanifestation of these forms, a diversified investigation seems to be 
worthwhile. This retrospective cohort study aimed to describe the longterm effects of ERT in eight 
Italian juvenile GSDII patients, starting therapy during childhood and being treated for at least 72 
months. Although most patients did not show muscle function impairment before therapy start, 
muscle enzymes were pathologically high in all of them, and the introduction of ERT resulted in an 
initial decrease and a subsequent stabilisation. This trend is consistent with previously published 
studies [8, 25]. Moreover, the improvement in CK concentrations as an effect of ERT is important, 
in the light of the possible role of CK as a sensitive marker of muscle damage [5]. Performances at 
6MWT, variable at therapy start, slightly improved in seven out of eight patients during the follow-
up. In fact, patients were able to walk longer distances, and in several cases, the respiratory and 
muscular fatigue after the test was milder, irrespective of the distance walked. A strength worth to 
be mentioned is that the metres walked at the 6MWT were normalised for age and gender. This 
adjustment is particularly important when children are investigated in a longitudinal fashion, since it 
allows a comparison with peers of the same age and gender, in order to prevent misinterpreting 
stability or increase in the metres walked as stabilisation or improvement, when it could even 
represent worsening. The pulmonary function remained quite stable in time in all the patients, 
whether they were impaired at baseline or not. This apparent absence of effect should be read in the 
light of the results of previous studies on late-onset untreated patients, describing a worsening in 
lung function and exercise tolerance [32, 38] and, especially, a loss of predicted FVC, ranging 
between 1.6 % per year [32] and 2.2 % in 18 months [34]. Moreover, our results are consistent with 
the improvement of functional exercise capacity and stabilisation of lung volumes already described 
in previous studies [3, 8, 25]. However, Van der Ploeg et al. suggested that the effect on both motor 
and pulmonary functions is larger in 
patients with higher residual muscular function at baseline, while in our patients, a similar trend is 
observed in all, irrespective of their baseline performance [34]. This may be explained by the 
difference between the two study groups, since Van der Ploeg described a cohort mainly 
represented by late-onset GSDII patients, mostly starting ERT over the third decade of life, while 
our patients received an early treatment during childhood and had, therefore, a shorter disease 
length. The BMI trends during the follow-up were variable at the individual level, but an overall 
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decrease could be observed, to be ascribed either to a weight loss or to a weight gain not appropriate 
for height. However, BMI—although adjusted for age and gender—does not allow to distinguish 
whether the muscle or fat tissues were lost; thus, opposite explanations can be suggested. First, 
patients with a better muscle function could practice more physical activity and, consequently, lose 
fat. On the other hand, patients finding exercise too tiring could practice less and, consequently, 
lose muscle. Therefore, it would be useful to evaluate body composition in GSDII patients, in order 
to understand the underlying mechanism of this decrease. In this study, unfortunately, body 
composition (as measured by dual X-ray absorbimetry total body scan) was not systematically 
assessed. In this paper, we describe five patients who started treatment during childhood, despite 
being asymptomatic. Interestingly, none of them developed muscle or respiratory symptoms after 6 
years of follow-up, all showed a decrease in muscle enzymes, and one normalised. These data 
suggest that early ERT initiation may prevent or, at least, delay the onset of GSDII symptoms. 
However, we do not know how the natural history of these patients would have been, in the absence 
of treatment. Treating these patients before the clinical onset is not a widespread therapeutic 
decision, and the optimal timing for therapy start in juvenile GSDII patients is still a debated issue. 
However, since ERT seems to be more successful when administered prior to irreversible muscle 
damage [34], it is reasonable to consider that ERT should be started before the frank clinical onset 
of the disease. In fact, ERT seems to be more efficient on preserved than on damaged muscle, as 
suggested by the characterisation of pre- and post-ERT histopathology in infantile forms, provided 
by Thurberg et al. [26]. In their research, some features, such as low glycogen levels, mild 
ultrastructural damage, high proportion of type I fibres and young age at ERT start, were associated 
with a good histological response to ERT. Therefore, an early treatment could allow young patients 
to have a slower deterioration in their muscular function. However, the correct timing for therapy 
start in juvenile GSDII patients is still controversial, since no randomised controlled trials were 
performed on this subject, and only small observational retrospective studies are available in the 
literature, preventing from drawing strong conclusions. Our study itself suffers from these 
limitations, analysing data from only eight heterogeneous patients in a retrospective fashion. 
Therefore, there is the crucial need for appropriately conducted research able to compare the 
effectiveness of different timings for ERT start. These studies should be experimental, multi-centric 
and sufficiently large to achieve the power to detect clinically relevant differences. 
 
In conclusion, our results suggest that ERT is effective in stabilising both motor and lung functions 
in juvenile patients with GSDII. However, well-conducted randomised controlled trials are 
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necessary to understand whether an early treatment allows juvenile patients to reach adulthood with 
a more beneficial residual muscular function than untreated patients. 
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Abstract 
 
Introduction: Late Onset Pompe disease (LOPD) is a progressive neuromuscular disorder in which 
impaired exercise tolerance is one of the clinical hallmarks. The specific enzyme replacement 
therapy (ERT) is administered to LOPD patients every two weeks. In clinical practice several 
LOPD patients refer a subjective improvement of exercise tolerance during the days immediately 
following the ERT infusion, and a gradual decrease during the 2 weeks interval between the 
infusions. In this study we investigated the acute effects of ERT on the main physiological variables 
associated with exercise tolerance in LOPD patients chronically treated with ERT. Furthermore we 
assessed whether the clinical severity of the disease and the habitual physical activity of patients 
would affect the investigated variables. 
Patient and Methods: the day before (B) and the day after (A) ERT injection, 11 patients with 
LOPD treated with ERT for more than 2 years, performed on a cycle ergometer a costant work rate 
exercise followed by an incremental exercise to voluntary exhaustion. Oxygen uptake (VO2), heart 
rate, ratings of perceived exertion, peripheral fractional O2 extraction and alpha glucosidase (GAA) 
activity on blood were determined in B and A. 
The disease severity was characterized by neurological examination, Walton scale, 6 minutes 
walking test (6MWT), and pulmonary function tests.  
Results: no significant difference in the main physiological variables related to exercise tolerance 
were found in A vs B, despite a significant increase in blood GAA activity. VO2 peak was 
significantly higher in patients with mild disease, while no differences in VO2 peak were observed 
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between patients with only skeletal muscle impairment and patients with both skeletal and 
respiratory muscle impairment. VO2 peak were progressively lower as a function of decreasing 
habitual physical activity. Distance walked at 6MWT was significantly higher than VO2 peak 
expressed as percentage of normal values. 
Conclusions: the exercise tolerance test is not acutely affected by ERT administration. The 
peripheral muscle component is prominent in determining the VO2 peak decrease, rather than the 
respiratory component in LOPD patients. The habitual physical activity improves the exercise 
tolerance, regardless the disease severity. The exercise tolerance test might be more sensible then 
the 6MWT in patients with mild LOPD. 
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Background 
In total, twenty-two patients with late onset Pompe disease (LOPD) are regularly followed at the 
Regional Coordinator Centre for Rare Diseases of the Academic Medical Centre Hospital of Udine. 
Among them, 16 are long term treated with ERT (more than 2 years of therapy). Everyone receive 
regular ERT injection at a dosage of 20mg/kg i.v., every 2 weeks, as for standard therapy.  
In clinical practice, many patients report a subjective improvement of general well-being and 
reduced fatigability during the days immediately following the ERT infusion, and a gradual loose of 
this positive effects during the two weeks interval between the infusions. This phenomenon could 
be attributed to acute effects of ERT on exercise tolerance.  
Exercise intolerance is a key clinical manifestation of LOPD which can be caused by multiple 
factors including respiratory and peripheral muscle function alterations (Muller Felber W et al 
2007; Alejaldre A et al 2012). As in many other pathological conditions (Maltais et al.2014; Poole 
et al.2012; Salvadego et al.2010), also in LOPD patients exercise intolerance may represent an 
important cause of the patients’ decreased perception of general well-being. The incremental 
exercise tolerance test, up to voluntary exhaustion, is a validated method to evaluate exercise 
(in)tolerance in several physiological and pathological conditions among which metabolic 
myopathies (Grassi B et al 2007; Grassi B et al. 2009). In 2012 Marzorati et al. demonstrated the 
positive effect of ERT on some physiological variables associated with exercise tolerance in 4 
patients with LOPD, after 1 year of therapy, and proposed this approach for the patients’ clinical 
assessment in their follow up (Marzorati M. et al 2012). Subsequently a few other studies have 
utilized protocols of incremental exercise tests, with the determination of cardiovascular, pulmonary 
gas exchange and metabolic variables, to evaluate exercise (in)tolerance in LOPD patients (Van den 
Berg L et al 2015, Crescimanno G et al 2015). However, the 6 minutes walking test (6MWT) 
remains the most commonly utilized method to estimate the patients’ exercise capacity in clinical 
practice and clinical trials (Bembi B et al 2010; Anderson LJ et al 2014). 
 
Aims 
The first aim of this study was to investigate the acute effects of ERT on the main physiological 
variables associated with exercise tolerance in LOPD patients chronically treated with ERT. The 
second aim was to assess whether the clinical severity of the disease would affect some of the 
investigated variables. The third aim was to assess whether the habitual physical activity of patients 
could influence the investigated variables. 
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Patients and methods 
Eleven out of twenty-two patients with LOPD followed at the Regional Coordinator Centre for Rare 
Diseases of the Academic Medical Centre Hospital of Udine, Italy, were enrolled in this study. 
Inclusion criteria were: confirmed diagnosis by enzyme assay and/or genetic testing; chronic (at 
least 2 years) ERT at a standard dosage of 20 mg/kg every 2 weeks; willingness to participate to the 
study. Exclusion criteria were: wheelchair bound; severe cardiac disease (assessed by 
electrocardiogram and echocardiography) or respiratory assistance 24h/day. All patients recruited, 
or their parents when under 18 years of age, gave informed consent. The study was approved by the 
local institutional ethics committee. All procedures were in accordance with the recommendation 
found in Declaration of Helsinki (2000).  
 
Clinical history was collected from clinical records. Before performing the study tests, patients were 
asked to indicate how they usually felt, in terms of general subjective well-being and fatigability the 
day before and the day after the ERT infusion. Habitual physical activity was evaluated by a 
questionnaire. 
Full neurological examination, six minutes walking test (6MWT) and pulmonary function testing 
(PFT) in the sitting position were performed by utilizing standard methods within 3 days from the 
study. Distance walked at 6MWT and forced vital capacity (FVC) at PFT were calculated as a % of 
predicted values (Enright PL et al 1998; Laslo G et al 2006). Patients were classified as having a 
respiratory involvement if FVC was <90% and/or if they were treated with non-invasive nocturnal 
ventilation (NIV). Global motor disability was assessed by the modified Walton scale (WS) (Slonim 
Ae et al 2006).  
 
At the study time, 24h before (BEFORE) and 24h after (AFTER) the ERT infusion, the patients 
underwent to blood samples collection, and then performed a modified exercise test (see below) to 
the limit of tolerance on a cycle ergometer. In all patients ERT was administered intravenously at 
the usual dosage and at the scheduled day (14 days after the previous injection).  
GAA activity was measured in lymphocytes using the fluorogenic substrate 4-methylumbelliferyl-
α-Dglucopyranoside (Glycosynth, Cheshire, England). Protein concentration of the samples was 
determined by the Lowry method. Enzymatic activity was expressed as nanomoles of substrate 
hydrolyzed per milligram of total protein per hour. All assays were done in triplicate. 
Serum levels of muscle enzymes (creatine phosphokinase CK, lactate dehydrogenase LDH, alanine 
transaminase ALT, and aspartate transaminase AST) were measured  by utilizing standard kits. 
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Exercise protocol 
 
Exercise tolerance testing was performed at the Exercise Physiology Laboratory of the University 
of Udine. Experiments were conducted under medical supervision, and patients were continuously 
monitored by 12-lead electrocardiography (ECG). A mechanically braked cycle ergometer (Monark 
Ergomedic 839E) was utilized. Pedalling frequency was digitally displayed to the subjects, who 
were asked to keep a constant cadence throughout the test, between 60 and 70 rpm. Each patient 
had chosen his preferred cadence during practice trials, and this cadence was maintained during 
each repetition. Patients were allowed time to gain familiarity with the researchers and the 
experimental set-up, were carefully instructed about the procedures and were familiarized with the 
protocol using short practice runs before starting the study. 
A specific functional evaluation test was utilized. The patients performed a low-intensity constant 
work rate (CWR) exercise for 8 minutes or until voluntary exhaustion, identified as the inability to 
maintain the desired cadence, despite verbal encouragement. In the patients who completed the 
CWR exercise, the test was immediately followed (no recovery period) by an incremental exercise 
up to voluntary exhaustion (Figure 1). During the CWR exercise work rate was selected according 
to the patient’s physical fitness level, estimated during preliminary practice runs (22.8 ± 15.6 W). 
During the incremental exercise, work rate was increased by 5-10 W every minute. 
Pulmonary ventilation (?˙?), tidal volume (VT), respiratory frequency (fR), O2 uptake (?˙?2) and 
CO2 output (?˙CO2) were determined on a breath-by-breath basis by means of a metabolic unit 
(Quark b2, Cosmed, Italy). Expiratory flow measurements were performed by a turbine flow meter 
calibrated before each experiment by a 3 L syringe at three different flow rates. Calibration of O2 
and CO2 analysers was performed before each experiment by utilizing gas mixtures of known 
composition. The gas exchange ratio (R) was calculated as ?˙CO2/?˙?2.. Arterial Oxigen saturation 
(SAO2) was determined by pulse-oximetry. 
 
 
Figure 1   Exercise tolerance test protocol adapted to late onset Pompe patients. 
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Heart rate (HR) was determined by ECG. Ratings of perceived exertion (RPE) was obtained at rest 
and at every minute during exercise by using the Borg’s modified CR10 scale (Borg 1998).  
Considering that only one CWR bout could be carried out, a formal ?˙?2 kinetics analysis was not 
performed (Lamarra et al. 1987). Mean	?˙?2 values were calculated during the last 30 seconds of 
every minute of exercise. The O2 cost of exercise was calculated during the last minute of the CWR 
exercise as ∆?˙?2 / ∆ work rate. One of the eleven subjects was only able to perform an unloaded 
pedalling and thus was excluded from the analysis of the O2 cost. For all variables (see below), 
values determined at voluntary exhaustion were considered “peak” values.  
Muscle oxygenation profiles of the vastus lateralis  during exercise were evaluated by near-infrared 
spectroscopy (NIRS) (Ferrari et al. 2011). NIRS measurements in muscle tissue have been shown 
to be well correlated with local venous O2 saturation (Boushel et al., 2001; Wüst et al., 2014; 
Vogiatzis et al., 2014). A portable NIR continuous-wave instrument (PortaMon, Artinis, The 
Netherlands) was utilized in this study (Salvadego et al. 2011; Salvadego et al. 2013). The 
instrument measures micromolar (µM) changes in oxygenated haemoglobin (Hb)+myoglobin (Mb) 
concentrations (∆[oxy(Hb+Mb)]), and in deoxygenated [Hb + Mb] (∆[deoxy(Hb+Mb)]), with 
respect to an initial value arbitrarily set equal to zero and obtained during the resting condition 
preceding the test. The sum of the two variables (∆[total(Hb+Mb)]) is related to changes in the total 
Hb volume in the muscle region of interest (Ferrari et al 2011). In contracting muscle, 
∆[deoxy(Hb+Mb)] is relatively insensitive to changes in blood volume and has been considered an 
estimate of skeletal muscle fractional O2 extraction (ratio between O2 consumption [?˙?2] and O2 
delivery [?˙?2]) (Ferreira et al., 2007; Grassi 2005; Kowalchuk et al., 2002). A "physiological 
calibration" of ∆[deoxy(Hb+Mb)] values was performed by obtaining a transient ischemia of the 
limb after the exercise period: data obtained during exercise were expressed as a percentage of the 
values of maximal muscle deoxygenation obtained by pressure cuff inflation (at 300-350 mm Hg), 
carried out at the inguinal crease of the thigh for a few minutes, until ∆[deoxy(Hb+Mb)] increase 
reached a plateau. 
 
Statistical analysis 
Results were expressed as mean values ± standard deviation (x ± SD). The statistical significance of 
differences between means was checked by paired two-sided Student’s t-test. The level of 
significance was set at p<0.05. Statistical analyses were carried out by utilizing commercially 
available software packages (Prism 5.0, GraphPad, USA; Statistical Package Social Sciences 15.0, 
SPSS Inc., USA).  
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Results 
Eleven Caucasian patients with LOPD (6 females and 5 males; age 30.9 ± 15.1 years) participated 
to the study; their anthropometric and clinical characteristics are summarized in Table 1. Two 
patients (pt 2 and 8) were brothers, the others were unrelated. 
Five out of eleven patients reported an acute improvement on their subjective wellbeing after ERT, 
one referred a worsening and 5/11 declared no difference. 
 
Enzyme activity was significantly higher in AFTER vs BEFORE (Figure 2), whereas no differences 
were found between serum muscle enzymes levels in AFTER vs BEFORE: CK 446 ± 143 mmol/l 
vs 427 ± 211 mmol/l, LDH 474 ± 110 mmol/l vs 487 ± 122 mmol/l, AST 52 ± 32 U/l vs 51 ± 32 U/l 
and ALT 49 ± 37 U/l vs 47 ± 35 U/l. 
Nine out of eleven patients were able to complete the 8-min CWR cycling test. Two patients (pt 5 
and 9) reached exhaustion earlier (after 5 and 7 min, respectively). One patient (pt 1) completed the 
CWR test, but could not perform the incremental test. Therefore, 8 out of 11 patients were able to 
perform the incremental test both in BEFORE and in AFTER. Data were analyzed during the last 
minute of the CWR exercise and at voluntary exhaustion. 
The exercise test was well tolerated, and no side effects occurred during and after the exercise. 
Arterial oxygenation did not decrease below 96% in all patients. 
All ventilatory, gas exchange, cardiovascular, and the VO2 cost of cycling did not differ in AFTER 
vs BEFORE (Table 2 and 3, Figure 3 and 4). 
Data on peripheral fractional O2 extraction, obtained by NIRS did not differ in AFTER vs BEFORE 
both during constant work rate exercise and at peak (Figure 5) 
Since no significant differences were observed in AFTER vs BEFORE, for further analyses only the 
data obtained in BEFORE were considered.  
Comparing the main data obtained in our cohort from the 6MWT and from the exercise tolerance 
test, the walking distance reached during the 6MWT, expressed as percentage of predicted values 
resulted significantly higher than the V’O2 peak (Figure 6). 
Finally, data were further analysed dividing patients in three classes on the bases of the disease 
severity: 1. No apparent symptoms: Walton scale score 0, no respiratory involvement (N group: 
including pt 2,4,6,10,11); 2. Skeletal muscle dysfunction: Walton scale score ≥ 2, no respiratory 
involvement (M group: including pt 1,3,7); 3. Skeletal and respiratory muscle dysfunctions: Walton 
scale score ≥1 plus respiratory involvement (M+R group: including pt 5,8,9).  
V’O2 peak was then analysed with respect of the 3 groups of increasing disease severity, and the 
results were significantly lower in M and in M+R vs. N, whereas V’O2 peak values in M and M+R 
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were comparable, both showing very low values (Figure 7), data expressed as a percentage of the 
values predicted for age- and sex-matched healthy normally active subjects (Wasserman et al., 
1999).  
Moreover, patients were divided in other 3 categories, depending on their level of habitual physical 
activity: 1. None: sedentary daily living (pt 1,5,7,8); 2. Moderate: active daily living (pt 3,4,6,9); 3. 
High: active daily living + regular exercise training. For 5 out of 11 patients there was no 
corrispondance between habitual physical activity level and degree of disease severity (Figure 8). 
V’O2 peak values, again expressed as a % of those predicted for age- and sex-matched healthy 
normally active controls, were progressively lower as a function of decreasing habitual physical 
activity (Figure 9). 
The values of O2 cost of cycling, obtained as ∆V
.
O2/∆ work rate during the CWR exercise, from 
the cohort of patients with LOPD evaluated in this study were markedly higher compared to values 
reported previously in normal subjects and in patient populations affected by other types of 
metabolic myopathies (mitochondrial disorders and Mc Ardle disease) (Grassi et al 2009) (Figure 
10). 
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patient age gender genotype height weight BMI years WS NIV FVC subjective  
code years 
 
c-/c- m kg 
kg/c
m2 
on 
ERT 
  
% wellbeing 
1 46 F 
-32-13T>G/ 
2481+102_2646+
31del 
1,64 50 18,6 2 3 no 108 better in A 
2 47 M 
-32-13T>G/ 
2646_2646+1del
TG 
1,9 112 31,0 4 0 no 112 unchanged 
3 19 M -32-13T>G/ unknown 1,78 60 18,9 7 2 no 107 unchanged 
4 17 M  
-32-13T>G/ 
2481+102_2646+
31del 
1,88 66 18,7 7 0 no 91 better in A 
5 43 F -32-13T>G/ 2237G>A  1,68 80 28,3 7 6 yes 64 better in A 
6 21 M -32-13T>G/ unknown 1,74 71 23,5 7 0 no 99 unchanged 
7 43 F N.A. 1,66 70 25,4 2 3 no 126 better in B 
8 53 M 
-3213T>G/ 
2646_2646+1del
TG 
1,85 106 31,0 7 3 yes 55 better in A 
9 20 F 692+1G>C/ 1645G>C 1,57 41 16,6 8 3 yes 22 better in A 
10 15 F -32-13T>G)/ 307T>G 1,6 59 23,0 8 0 no 106 unchanged 
11 16 F -32-13T>G)/ 1465G>A 1,62 57 21,7 7 0 no 102 unchanged 
mean 30,9 
  
1,7 70,2 23,3 6,0 
  
90,2   
SD 15,1 
  
0,1 21,9 5,1 2,2 
  
30,7   
 
 
 
Table 1. Anthropometric and clinical characteristics of patients 
BMI: body max index; ERT: enzyme replacement therapy; WS: Walton scale score; NIV: nocturnal 
non invasiv ventilation; FVC: forced vital capacity. 
A: the day after the ERT injection, B: the day before the ERT injection 
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PARAMETER before ERT after ERT 
  mean± SD mean ± SD 
WR watt 25 ± 12,8 25 ± 12,8 
V'E L/min 26,2 ± 4,6 28,2 ± 4,5 
fR breath/min 27,9 ± 10,9 27,2 ± 11,0 
VT L/min 1,1 ± 0,4 1,2 ± 0,6 
V'O2 ml/min 879,3 ± 195,5 907,8 ± 200,0 
V'O2 ml/min/kg 13,3 ± 3,2 13,7 ± 3,4 
V'CO2 ml/min 865,4 ± 163,7 900,7 ± 163,8 
R 0,99 ± 0,08 1,00 ± 0.07 
PETO2 mmHg 103,4 ± 4,9 104,1 ± 5,1 
PETCO2 mmHg 38,6 ± 2,9 38,5 ± 2,5 
HR beat/min 119,8 ± 21,8 122,2 ± 15,2 
RPE 2,7 ± 2,7 2,9 ± 3,3 
V'O2 cost ml/min/watt 22,0 ± 5,2 23,4 ± 6,4 
   ∆[deoxy(Hb+Mb)] (% of ischemia) 25,2 ± 15,4 28,1 ± 19,1 
 
 
Table 2. Values of the main investigated paramenters during the contant-work rate exercise 
before and after ERT 
Means ± SD of the main physiological variables determined during the last minute of the costant 
work rate cycle ergometer exercise. WR: work rate; V'E: pulmonary ventilation; fR: respiratory 
frequency; VT: tidal volume; V'O2: O2 uptake;  V'CO2: CO2 output; R: respiratory gas-exchange 
ratio, PETO2: O2 end-tidal pressure; PETCO2: CO2 end-tidal pressure; HR: heart rate;  RPE: 
ratings of perceived exertion; V'O2 cost: ∆ V'O2/∆work rate. 
∆[deoxy(Hb+Mb)]: NIRS-derived changes in deoxygenated Hb+Mb concentrations at the vastus 
lateralis muscle, expressed as a percentage of the maximal values obtained during a transient limb 
ischemia. 
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PARAMETER before ERT after ERT 
  mean ± SD mean ± SD 
WRpeak watt 74,5 ± 55,1 77,3 ± 59,0 
V'Epeak L/min 44,7 ± 19,4 44,7 ± 19,2 
fRpeak breath/min 32,3 ± 10,2  31,2 ± 11,6 
VTpeak L/min 1,5 ± 0,7 1,6 ± 0,8 
V'O2peak ml/min 1371,8 ± 672,6 1393,2 ± 654,2 
V'O2peak/BM ml/min/kg 19,9 ± 7,3 20,4 ± 8,3 
V'CO2peak ml/min 1498,4 ± 686,4 1563,6 ± 767,1 
Rpeak 1,09 ± 0,08 1,10 ± 0,11 
PETO2peak mmHg 106,9 ± 5,3 106,3 ± 7,4 
PETCO2peak mmHg 38,6 ± 4,4 39,1 ± 5,3 
HRpeak beat/min 146,4 ± 21,6 150,1 ± 22,3 
RPEpeak 5,7 ± 2,3  5,8 ± 2,9 
Time to exhaustion min 13,2 ± 4,8 13,5 ± 5,1 
   ∆[deoxy(Hb+Mb)]peak (% of ischemia) 53,9 ± 21,3 56,3 ± 23,0 
 
 
Table 3. Peak values of the main investigated parameters before and after ERT 
Means ± SD of the main physiological variables determined at peak (voluntary exhaustion). WR: 
work rate; V'E: pulmonary ventilation; fR: respiratory frequency; VT: tidal volume;  V'O2: O2 
uptake;  V'CO2: CO2 output; R: respiratory gas-exchange ratio, PETO2: O2 end-tidal pressure; 
PETCO2: CO2 end-tidal pressure; HR: heart rate;  RPE: ratings of perceived exertion. 
∆[deoxy(Hb+Mb)]: NIRS-derived changes in deoxygenated Hb+Mb concentrations at the vastus 
lateralis muscle, expressed as a percentage of the maximal values obtained during a transient limb 
ischemia. 
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Figure 2. GAA activity on leukocites. Data obtained from blood samples of all patients. 
* p<0.05 
The figure show a significantly higher GAA activity (measured on leucocytes) in after vs before. 
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Figure 3: main measured variables during constant work rate exercise, before and after ERT. 
The figure show no difference in pulmonary O2 uptake, heart rate, gas exchange ratio and ratings of 
perceived exertion in after vs before. 
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Figure 4. main measured variables at peak, before and after ERT. 
The figure show no difference in peak work rate, peak pulmonary O2 uptake (peak VO2), peak rate 
of perceived exertion (RPE), peak heart rate, in after vs before. 
Patients with Pompe disease included in this study show levels of peak VO2 notably low (normal 
values around 3L/min). 
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CONSTANT WORK RATE EXERCISE 
Vastus lateralis fractional O2 extraction     
 
 
INCREMENTAL EXERCISE 
Vastus lateralis peak fractional O2 extraction 
 
 
Figure 5. Fractional O2 extraction at constant work rate exercise and at peak before and after 
ERT. 
Data obtained by near infrared spectroscopy (NIRS). The figure show no difference in fractional O2 
extraction, both during constant work rate exercise and at peak in after vs before. 
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Figure 6. Relationship between 6-min walking distance and peak pulmonary V’O2 
* p<0.05 
The figure show a significant reduction of VO2 peak measured by the exercise tolerance test, 
compared to the distance walked at the 6 minutes walking test (6MWT), with data expressed as 
percentage of predicted normal values. 
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Figure 7. Peak pulmonary V’O2 as a function of disease severity 
N: no apparent symptoms  ; M: skeletal muscle dysfunction ; M+R: skeletal and respiratory muscle 
dysfunctions. 
*: p<0.05 vs. N group 
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Figure 8. Lack of correspondence between disease severity and level of habitual physical 
activity in our cohort 
NC= no correspondence, 5/11 patients 
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Figure 9. Peak pulmonary V’O2 as a function of habitual physical activity 
High: active daily living + regular exercise training; Moderate: active daily living; None: sedentary 
daily living. 
*: p<0.05 vs. High group 
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Figure 10. O2 cost of cycling during CWR in LOPD 
Lines denote the mean values of the O2 cost of cycling previously determined in healthy subjects 
(CTRL), patients with mitochondrial myopathies (MM), and  patiens with McArdle’s disease 
(McA) (from Grassi et al., 2009).  
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Discussion 
In patients with LOPD, as in patients affected by other neuromuscular disorders, exercise 
intolerance is one of the clinical hallmarks of the disease, and can significantly affect the patients’ 
quality of life (Müller-Felber W et al 2007). Enzyme replacement therapy (usually carried out by an 
intravenous infusion every 2 weeks) has been demonstrated to ameliorate exercise tolerance 
evaluated after one year of treatment (Marzorati et al. 2012), but its effects after an acute infusion 
have never been investigated before.  
Empirically, some LOPD patients refer a subjective improvement of exercise tolerance during the 
days immediately following the ERT infusion, and a gradual decrease during the 2 weeks interval 
between the infusions.  
In the present study a novel and specific protocol of exercise test was utilized, composed of two 
consecutive parts (see Methods). In the first part the patients performed for 8 minutes a light-
intensity CWR exercise. Analysis of physiological variables during the last minute of the exercise 
allowed an objective evaluation of exercise tolerance also in the patients who, as a consequence of 
early fatigue (a frequent finding in LOPD patients) could not continue to perform the subsequent 
incremental portion of the protocol. More specifically, the observation of lower R, lower RPE, 
lower HR, lower O2 cost, and greater time to exhaustion would indicate an improved exercise 
tolerance. However, no differences were observed for any of these variables in AFTER vs 
BEFORE. The same conclusion can be drawn also for the more “traditional” peak values, 
determined during the incremental portion of the test. During both parts of the protocol no 
differences were observed, in AFTER vs. BEFORE, for the NIRS-obtained variable which we 
utilized to estimate skeletal muscle fractional O2 extraction.  
Thus, our results do not confirm an acute effect of ERT on physiological variables related to 
exercise tolerance, and do not confirm a decreased exercise tolerance during the 2 weeks between 
interventions, despite 6/11 patients reported a difference in their subjective wellbeing. The absence 
of any acute effect on exercise tolerance occurred despite a significant increase in GAA activity in 
blood in AFTER vs BEFORE. A note of caution is however necessary in this respect, since GAA 
was determined in blood, but not in skeletal muscle. Determination of GAA in muscle would need a 
muscle biopsy, which could not be carried out in the present study for ethical reasons.  
The lacking of an acute effect of ERT on the main variables of exercise tolerance can be explained 
by the pathophyisiology of muscle damage in LOPD patients, and the mechanism of action of the 
ERT in muscle cells. In these patients there is an impairment of lysosomal glycogenolysis, linked to 
the GAA defect, while the cytoplasmic breakdown of glycogen by myophosphorylase is unaffected. 
During exercise muscle cells utilize cytoplasmic glycogen as a source of energy, while the 
65 
 
lysosomal glycogen is preferentially utilized at rest (McArdle et al 2007; Preisler N et al 2012). The 
ERT helps the cell to break down lysosomal glycogen, resembling the endogenous GAA enzyme, 
but does not act on cytoplasmic glycogenolysis. This may explain the absence of acute effects of the 
drug on exercise tolerance. The positive effects of ERT in LOPD patients would then be 
substantially related to the long term effects of the drug on the chronic alteration of muscle cells 
structure secondary to the disease (Marzorati et al 2012), and therefore they cannot be seen after a 
single administration. The effect on subjective wellbeing after an acute ERT administration, 
reported by some patients, can be linked to other factors, which cannot be detected with an exercise 
tolerance test. Is it possible to hypothesize a role of ERT in acutely reducing the inflammation 
likely associated with Pompe disease. In fact lysosomal dysfunction and its consequent abnormal 
autophagy can trigger a pro-inflammatory status (Ryter SW et al 2014), and muscular inflammation 
has been described in autoptic specimens of LOPD patients (Hobson Web LD et al 2012). However, 
although a positive effect of ERT on inflammation has been demonstrated in other lysosomal 
storage disorders (Ko Y wet al 2015), it has never been investigated in LOPD patients, and further 
studies are needed to confirm this hypothesis. It must be also pointed out that not all patients in our 
cohort (5/11) reported an acute improvement on their subjective wellbeing after ERT, one of them 
referred a worsening and 5/11 declared no difference, therefore we cannot exclude a psychological 
effect. 
A practical consequence to the absence of changes of the main physiological variables related to 
exercise tolerance with an acute ERT administration is that this type of functional evaluation can be 
performed in the patients’ follow-up independently from the timing of the ERT infusion. Moreover, 
the study highlights the importance of using this functional evaluation test for assessing the 
patient’s outcome in a long term. Nowadays the 6MWT is a widely used method to assess muscular 
function during the progression and the treatment of LOPD, however, considering the minimal 
differences of the distance covered among LOPD patients, alternative outcome measures should be 
found (Lachmann et al 2013). Interestingly, our data suggest that the functional evaluation test 
might be more sensitive in evaluating exercise limitations in patients with LOPD than the standard 
6MWT. In fact in our cohort, the distance covered during the 6MWT was closer to the predicted 
values referred to healthy subjects than the V’O2 peak values measured during the exercise 
tolerance test, which resulted compromised even in those patients with apparently no symptoms. 
Our data are in contrast with a recent study by Crescimanno G et al, in which the two tests showed a 
similar overall degree of exercise impairment in a cohort of 8 LOPD patients (Crescimanno G et al 
2015). Nevertheless, the population included in that study was older and more clinically 
compromised than patients included in the present study. Therefore, we suggest the use of the 
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exercise tolerance test in the clinical practice to detect early changes in patients with LOPD, 
especially in those with a mild disease. 
 
In the present study interesting insights, in our opinion, may also derive from the evaluation of 
V’O2 peak after the subdivision of patients in different categories on the basis of the clinical 
severity of the disease (Figure 4). As it could be expected, patients who were apparently free of 
symptoms had a higher V’O2 peak, while lower V’O2peak values were observed in patients with 
skeletal muscle impairments and in patients with both skeletal muscle and respiratory impairments, 
with no differences between the two subpopulations. Similar findings were previously observed in 
patients affected by other chronic diseases characterized by both pulmonary and skeletal muscle 
alterations (Maltais et al., 2014; Salvadego et al., 2015) and in healthy subjects exposed to 
prolonged muscle inactivity and hypoxia (Salvadego et al., 2011; Salvadego et al., 2016). 
Moreover, patients grouped for habitual physical activity level showed significant differences in 
their performances: decrease in moderate vs high and none vs high, and a trend to decrease, even if 
not statistically significant, in none vs moderate. These data are important considering that in 5 out 
of 11 patients there was not correspondence between the degree of their clinical severity and the 
level of their physical activity since some patients who could potentially perform more exercise had 
a sedentary lifestyle and some patients more clinically compromised used to perform regular 
exercise, as well as possible for their clinical conditions. Thus, we can postulate that increasing 
habitual physical activity, with adequate training, could improve the exercise tolerance even in 
patients who already show motor and respiratory impairment. This is in accordance with previous 
studies who propose regular physical activity to ameliorate the clinical status in patients with LOPD 
(Slonim AE et al 2007; Van den Berg L et al 2015). 
 
In this study, LOPD patients also showed markedly higher values of the O2 cost of cycling 
compared to healthy subjects and to patients affected by other forms of muscle disorders (Figure 5) 
which directly involve the metabolic pathways (Grassi et al., 2009). Overall these findings suggest 
that in LOPD patients, the disease-related muscle damage and the resulting muscle dysfunction can 
play a key role in limiting oxidative performance and exercise tolerance. 
 
This study suffers from several limitations. One of the limitations of the incremental exercise test in 
LOPD patients, as in other patients with neuromuscular disorders, is represented by the fact that 
profound muscle weakness or muscle pain may preclude the performance of an effective test. For 
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that reason we utilized a modified protocol of exercise tolerance test adapted to LOPD patients, 
where the incremental part was preceded by a light-intensity constant work rate exercise. 
A further limitation of this study lies in the fact that after subdividing the patients into different 
subgroups the number in each subgroup became very small. Further larger studies are needed to 
confirm our insights.  
 
Conclusions 
In conclusion, in patients with LOPD under chronic treatment with ERT the administration of the 
drug does not have any acute significant effect on several physiological variables related to exercise 
tolerance. No changes of these variables were observed during the 2 weeks period between 
infusions. On the contrary, we suggest to perform exercise tolerance test to assess the outcome of 
LOPD patients in the long term, especially in patients with a mild disease to detect early changes in 
clinical status.   
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Study III 
 
Exercise tolerance in patients with late onset Pompe disease on enzyme 
replacement therapy: effect of exercise training and hyperproteic diet 
 
This study won a 3 years grant from the “ministero della salute Italiana” through “bando della 
ricerca finalizzata, giovani ricercatori 2011-2012” and, at present, is still ongoing. 
In this thesis I report the preliminary results. 
 
 
Abstract 
Background: Late onset Pompe disease (LOPD) is a progressive neuromuscular disorder which 
can lead to important disability and impaired quality of life. The effect of the specific enzyme 
replacement therapy (ERT) in the long term is limited. Functional evaluation of exercise tolerance 
is a recent tested method to evaluate patient’s clinical outcome. Before the introduction of ERT, the 
positive effects of diet and exercise training had been demonstrated in LOPD, but the effect of these 
interventions on patients treated with ERT is still debated and poorly known. The aim of this study 
is to evaluate if exercise training, alone or in combination with diet therapy, can improve exercise 
tolerance, motor functions and quality of life in LOPD patients chronically treated with ERT. 
Patients and methods: a cross-over study was designed. LOPD patients were selected from two 
different clinical units in Udine and Milan. Participants were assigned to a sequence of two 
treatments (exercise alone; exercise and diet) and one control period, each lasting 26 weeks, 
followed by a 13-week wash-out. Exercise tolerance test, muscular strength, 6-minute walking test, 
serum muscular enzymes (AST, ALT, CPK, LDH), pulmonary function tests, body composition 
and quality of life (SF36 questionnaire) are evaluated before and after each period. 
 
Preliminary Results: The study is ongoing. At present 12 patients have been enrolled. Only three 
patients have completed 2 intervention periods, 2 patients have completed one intervention period, 
all the others are under the first intervention period. For those who completed at least one 
intervention period, exercise training at home was feasible and safe. The compliance was higher for 
exercise therapy compared to diet therapy. Exercise improved inferior and superior arm force, VO2 
max and peripheral oxygen extraction. 
Conclusions: our preliminary data indicates a positive effect of exercise training in LOPD patients 
under chronic ERT, nevertheless we should wait the end of the study to draw proper conclusions. 
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Background 
The late-onset phenotype of Pompe disease (LOPD) is characterized by lysosomal accumulation of 
glycogen in skeletal and respiratory muscles, resulting in progressive weakness, motor dysfunctions 
and respiratory distress. The consequence in the long term can be invalidating, since the muscle 
damage in LOPD can progressively lead patients to severe motor limitations, with need of using a 
wheelchair, and to respiratory insufficiency with necessity of a respiratory support [Winkel LP et 
al2005]. Comprehensibly, the quality of life of this patients can be impaired. Exercise intolerance 
appears early in the natural history of the disease, and is one of the first clinical hallmarks affecting 
patients' quality of life [Mazorati M et al 2012]. In 2006, the enzyme replacement therapy (ERT) 
with recombinant alfa-glucosidase became available, and showed to be effective on motor and 
respiratory functions of LOPD patients [Van der Ploeg A et al 2010; de Vries JM et al 2012], and to 
improve their quality of life [Güngör D et al 2016]. However, different authors observed that the 
positive effects of ERT are evident in the first years of treatment but seem to stabilize or even 
decline afterwards [Bembi B et al 2010 Regnery C et al 2012]. Before the introduction of ERT, the 
positive effects of diet and exercise training had already been demonstrated in LOPD [Slonim AE et 
al 2006] but the effect of these interventions on patients treated with ERT is still debated and poorly 
known.  
Hour hypothesis is that exercise training, alone or in combination with hyperproteic diet, could 
improve exercise tolerance, motor function, muscle strength and consequently quality of life in 
LOPD patients on chronic ERT treatment. The ratio comes from cell pathology. In fact, at muscle 
fibre level the aerobic exercise could modify the energetic metabolism, increasing the use of fatty 
acids as an alternative source of energy, thus reducing proteolysis, autophagy and muscle 
destruction [Slonim AE et al 2006]. Moreover, exercise training could counteract the general 
deconditioning typical of chronic diseases as well as the chronic inflammatory condition associated 
with inactivity [Pedersen BK et al 2011]. Positive effects of exercise training have been already 
demonstrated in a study on Pompe mutant mice, in which animals under treadmill training 
improved aerobic capacity, strength and motor functions [Nilsson MI et al 2012]. 
The hyperproteic-low carbohydrate diet could reduce glycogen deposition in muscle cells and 
increase the intracellular protein synthesis, thereby reducing glycogen accumulation, proteolysis, 
muscle autophagy and damage [Slonim AE et al 2006]. Since diet and exercise act on different 
mechanisms, hour hypothesis is that their combined effect could be synergic. The expected 
improvement in the muscular functions could translate in an amelioration in patients' everyday life 
activities and quality of life. 
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The primary aim of this study is to evaluate the effects of an individualized exercise training 
program (alone or combined with a hyperproteic diet), on exercise tolerance, muscle functions and 
quality of life in LOPD patients chronically treated with ERT. 
The secondary aim is to evaluate the compliance with the proposed intensive life-style intervention. 
 
Patients and methods 
This study belongs to a collaboration between 3 different Units: The Regional Coordinator Centre 
for Rare Diseases of the Academic Hospital of Udine, the Exercise Physiology Laboratory of the 
University of Udine and the Neuromuscular Unit of the Carlo Besta Institute in Milan. 
Different professional figures are involved, including metabolic physicians expert in Pompe 
disease, neurologists, physiologist with experience in exercise functional studies, dietician and 
nurses. 
 
Patients were recruited from the 2 different clinical centres in Udine and Milan. 
Inclusion criteria were:  
1. age ≥18 years,  
2. diagnosis of LOPD confirmed by enzymatic test and/or genetic analysis,  
3. enzyme replacement therapy for at least two years. 
 
Exclusion criteria were:  
1. significant cardiovascular disease, 
2. wheelchair bound 
3. severe respiratory insufficiency;  
4. pregnancy, 
Patients who already performed regular physical activity or were on diet therapy were also 
excluded. 
The study was approved by the local Ethical Committee both in Udine and in Milan.  
Informed consent was obtained from all patients before starting study tests. 
 
The study was designed as a partially blinded crossover study. Blinding is applied to researcher 
working at laboratory assays, instrumental testing and data analysis.  
Participants were assigned to a sequence of two treatments (exercise alone; exercise and diet) and 
one control period (free diet, no exercise training), each period lasting 26 weeks and followed by a 
13-week wash-out.  
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Patients continue ERT during all the study period, at the usual dosage (20 mg/kg/b.w.). 
Aerobic exercise (performed at home) consist of a 4 sessions/week, 1 hour/session, personalized 
training program. Each session includes: warm-up, stretching and balance exercises (10-15 
minutes); strength training with very moderate loads of the main muscle groups carried out by 
elastic bands (15 minutes); a constant work-rate exercise on a cycle ergometer at 60% of the 
patient's maximal heart rate (HR) (30-40 min). Cycle ergometer with a HR-meter was shipped to 
each patient's domicile. The HR-meter allows the downloading of data on a personal computer. 
Hyperproteic diet is tailored by a specialist dietician to each patient according to the usual calorie 
intake, and is composed of 25-30% protein, 30-35% carbohydrate, and 35-40% fat. 
The effectiveness of interventions is evaluated measuring exercise tolerance (maximal aerobic 
power; gas exchange threshold; kinetics of pulmonary gas exchange during constant work-rate 
exercises; skeletal muscle fractional O2 extraction by near-infrared spectroscopy; HR, pulmonary 
ventilation and gas exchange ratio during constant work-rate exercise; rates of perceived exertion; 
time to exhaustion), muscular strength (as measured by dynamometer), motor function (6-minute 
walking test [6MWT], WS), neurologic functional tests, Walton scale score, serum muscular 
enzymes (AST, ALT, CPK, LDH), pulmonary function (standard spirometry, Maximal Inspiratory 
Pressure, Maximal Expiratory Pressure [MIP e MEP]), body mass index, body composition (by 
impedentiometry), before and after each period. 
Neurologic functional tests includes GSGC scores (Gait, Stairs, Gower, Chair). 
Quality of life is evaluated using the validated, standardized Italian version of SF36 questionnaire, 
administered both before and after each intervention. 
To check for compliance, patients are asked to complete a 3-day food diary every month, and a day 
by day physical activity diary during the period of intervention including the exercise. Moreover 
data from HR-meter during the treatment periods are collected. 
Low compliance risk is minimized through periodical contacts, by phone or e-mail, between 
participant patients and the study staff. 
 
Statistical analysis 
Since few patients at present have completed more than one intervention period, no statistical 
analysis was possible for this thesis. Preliminary data are shown as mean ± standard deviation (SD) 
when stated. 
At the end of the study, after checking for the absence of a carry-over effect (ANOVA; graphical 
assessment), a paired statistical analysis will be performed using a mixed-effects linear model to 
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account for the repeated measurements that yield period, sequence, and possible carryover effects 
and to model the various sources of intra-patient and inter-patient variability. 
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Preliminary results 
At present, 12 patients have been enrolled in this study. 
Six patients, 3 males and 3 females, all caucasian, have been enrolled in Udine. One more female 
patient will be enrolled in the study in the next future. Three patients have completed 2 intervention 
periods, 2 patients have completed one intervention period, one patient started the first intervention 
period recently. 
Other 6 patients have been enrolled in Milan and have completed one intervention period (data not 
available). 
General characteristics of patients enrolled in Udine are summarized in table 1 and 2. 
 
patient 
code gender 
age at 
diagnosis 
age at study 
entry genotype  genotype 
  m/f     allele 1 allele 2 
UD01 M 3 20 c.-32-13T>G c.2481+102_2646+31del 
UD02 M 41 49 c.-32-13T>G  c.2646_2646+1delTG 
UD03 F 29 50 c.-32-13T>G c.2481+102_2646+31del 
UD04 M 35 57 c.-32-13T>G  c.2646_2646+1delTG 
UD05 F 25 46 c.-32-13T>G  c.2237G>A 
UD06 F 29 42 not assessed not assessed 
 
 
patient  
code years on ERT comorbidities echocardiography ventilatory support 
          
     UD01 9 none normal none 
UD02 6 hypertension mild left ventricular hypertrophy none 
UD03 6 osteoporosis normal none 
UD04 9 hypertension aortic root ectasia NIV 
UD05 9 asthma; hypertension mild mitral valve 
regurgitation NIV 
UD06 8 none mild mitral valve regurgitation NIV 
 
Table 1 and 2. general characteristics of patients enrolled in Udine 
NIV: non invasive nocturnal ventilation 
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All patients had the genotype c.-32-13T>G on one allele, which is characteristic of patients with the 
late-onset form of Pompe disease (table 1). One patient (patient 1) have the juvenile form of the 
disease, the others have the adult form.  
Unless patients with late onset Pompe disease are generally considered free of cardiac symptoms, 
performing echocardiography we could evidence that 4 out of 6 patients had a cardiac abnormality 
(table 2), even though mild. Of note, 3 patients suffers from arterial hypertension, and take 
chronically medications for it. Three out of 6 patients need the use of respiratory support (non 
invasive ventilation) during night-time.  
The study tests were well tolerated in all cases and, for those patients who already performed the 
exercise at home, no adverse events were reported. 
Patient 1 and patient 3 completed the control period and the exercise period, patient 2 completed 
the control period and the exercise + diet period, patient 4 completed only the control period, 
patient 5 completed only the exercise + diet period, patient 6 just started the exercise period. 
The compliance with the proposed interventions was very high as for the aerobic exercise, while 
more difficulties were referred in following the diet, especially as regards patient 5. All patients 
referred better subjective wellbeing and less fatigability after the exercise period, they also refer a 
difficulty in stopping the exercise for the 3 months of washout after the training period, but were 
adherent to it. 
Not a specific trend was recognised as for values of CK in blood, distance walked at the six minutes 
walking test and vital capacity at spirometry, before and after each intervention period. 
Patients who performed the exercise period (1 and 3) had in increase in the legs and arm extensor 
muscles force, after the training program at home (figure 1a and 1b). 
Data obtained by NIRS showed an improvement in peripheral oxygen extraction, measured as 
∆[deoxy(Hb+Mb)], both after the exercise period for patients 1 and 3 and after the exercise + diet 
period for patient 2, while there was no difference before and after the control period (figure 2a, 2b, 
2c). 
As regards the VO2 max, a slight increase was observed after the exercise period, while not after 
the exercise + diet period (figure 3a, 3b and 3c). 
No evident changes were observed in BMI or in body composition in terms of lean body mass or fat 
mass, as measured by impedentiometry.  
 Figure 1a. Force of the knee extensor muscles before and after the 
 
 
Figure 1b force of the elbow extensor muscles before and after the 
 
 
 
Data are expressed as mean ± SD
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 Figure 2a vastus lateralis peak fractional O2 extraction 
 
 
 
Figure 2b v. lateralis peak fractional O2 extraction 
 
 
 
Figure 2b v. lateralis peak fractional O2 extraction 
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 Figure 3a. VO2 max before and after the
 
 
Figure 3b. VO2 max before and after the
 
Figure 3c. VO2 max before and after the
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Discussion 
As far as we know, this is the first study investigating the effect of an hyperproteic diet and a 
personalized aerobic exercise on patient with Pompe disease long term treated with enzyme 
replacement therapy. When the ERT was still not available, many clinician use to prescribe diet and 
exercise to patients, following the data by Slonim et al, which published the results of a 10 years 
retrospective study on 34 patients with LOPD treated with what they called NET (nutrition and 
exercise therapy) [Slonim AE et al 2007]. Slonim first noted that the degree of glycogen deposition 
in Pompe pathology was not proportional to the severity of the myopathy, realizing that there was 
an increase in proteolysis contributing to the muscle damage. That was confirmed by a rapid fall in 
plasma aminoacid levels following a protein load ingestion in a child with Pompe disease, that was 
successfully treated thereafter with hyperproteic diet, improving muscle function and exercise 
tolerance [Slonim Ae et al 1983]. Subsequently he proposed to treat patients with the NET, 
formulated to decrease glycogen deposition, counteract proteolysis and promote fatty acid 
utilization in muscles. The hyperproteic diet consisted in 25-30% protein, 30-35% carbohydrate, 
and 35-40% fat, the same utilized in our study. Patients on NET also took supplements of the 
aminoacid L-Alanine, which was not utilized in this study since further studies failed to 
demonstrate the clinical efficacy of this supplementation [Mundy HR et al 2006]. Exercise of NET 
consisted in a treadmill program daily for 45-50 min, followed by aerobic upper-body exercise for 
10-15 min. We choose exercise on a cycle-ergometer to allow also the participation of patients who 
had ambulatory difficulties, and proposed only for 4 sessions a week, to be more compatible with 
everyday life, and increase compliance. Among the patients on NET, 26 were considered in good 
compliance with the proposed interventions and 8 were considered not compliant. Rate of 
deterioration (as measured by Walton Scale) on NET was compared with each patient’s rate of 
deterioration before starting the NET, evidencing that the more compliant patients responded far 
better than those who became less active and did not follow the diet [Slonim Ae et al 2007]. 
After the advent of ERT for Pompe disease only few studies have been published investigating the 
effects of exercise on patients already on therapy, and no studies investigate the effect of the 
hypeproteic diet associated to exercise. 
In 2011 Terzis G et al. reported the effects of a 20-week exercise training in 5 LOPD patients 
receiving ERT. A significant increase in muscular strength (15-50% at various body parts) and 
distance walked at the 6-minute walking test (203.8 ± 177 m before vs. 248.2 ± 184 m after) was 
observed after training, suggesting a positive effect on muscular function and functional capacity. In 
this study total and lower extremities lean body mass did not change significantly [Terzis G et al 
2011]. The same group investigated the possibility to increase the effectiveness of the ERT, in 
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patients already on regular exercise training, if the exercise training was performed during enzyme 
infusion for 6 months, but the results did not show a further improvement [Terzis G et al 2012]. 
More recently, Van der Berg et al performed a larger study, including 25 patients with LOPD who 
performed a 12 weeks exercise training, continuing regularly ERT infusions. The prescribed 
exercise consisted in 3 sessions a week of a training combining aerobic, resistance and core stability 
exercises, utilizing a cycloergometer and other gym instruments such as chest press, biceps curl, leg 
press and leg curl After 12 weeks of training VO2 peak, maximum workload capacity and ventilator 
threshold improved significantly, maximum heart rate and forced vital capacity did not change. 
There was also an increase in strength of the hip flexors and the shoulder abductors. Functional 
neurological tests evidenced an improvement in time to climb four steps and time to rise from 
supine to a standing position. The distance walked at the 6 minutes walking test increased by 6%. 
Two patients experienced significant increase of CK (up to 10125 U/l in one case) with muscle pain 
and fatigue during the first weeks of training, but continued training with the resolution of 
symptoms. There were no changes in lean body mass or in fat mass. This study was very important 
to demonstrate that the composed training program can be safe for patients with Pompe disease and 
can improve muscle functions in patients already on enzyme replacement therapy [Van der berg LE 
et al 2015]. 
Finally, Krase et al. reported the clinical case of a patient on ERT who performed regular aerobic 
exercise, who voluntary withdraw the ERT, continuing only the exercise for 3 years. As reported by 
authors, muscle strength decreased 1 year after withdrawing from ERT, whereas it was restored 
during the last 2 years of exercise per se. FVC decreased during ERT per se, recovered with ERT + 
exercise and slightly decreased with exercise per se. Six minutes walking distance was increased 
during the first 12 months after initiation of ERT and remained unaltered thereafter [Krase et al 
2016]. 
Although our data are only partial and the study is still ongoing, some general consideration can be 
elicited from our preliminary data. First of all, our proposed aerobic exercise can be feasible and 
well tolerated even in patients who have already a respiratory insufficiency, needing a respiratory 
support during night time. Moreover, the exercise at a cycloergometer is more practicable than the 
exercise at the treadmill for patients with LOPD who often have walking difficulties. For the same 
reason, evaluation of exercise tolerance in these patients is more appropriate with a cycloergometer 
test.  
Our patients founded exercise easy to practice at home and referred beneficial effect on their 
subjective wellbeing. Our preliminary data suggest a positive effect of exercise especially on 
muscle strength of selected muscles, a better exercise tolerance in terms of increased VO2 max and 
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a better peripheral muscle oxygenation, as evidenced by the data of the NIRS. As regards the 
association between exercise and diet we did not see better results after the exercise+diet 
intervention period compared to before, but it must be pointed out that only two patients have 
already completed the exercise+diet period, one of which was completely not compliant with the 
proposed diet. Previous studies, performed before the advent of ERT, evidenced that only 25% of 
patients showed improvement in muscle or respiratory functions after a high iperproteic diet, but the 
compliance with the diet was very poor in most studies. Compliance following the introduction of a 
high-protein diet is often poor due to the large quantities of protein necessary, and a perceived risk 
of weight gain [Bodamer OA et al 1997]. With the aim to improve the adherence to the proposed 
diet for the next patients who will face the exercise + diet period, we will increase the number of 
contacts with the dietician and try to maximally personalize the proposed nutrition scheme, to be 
more feasible in everyday life.  
Interesting insights are waited by the end of our study. Compared to the study of Van der Berg et al. 
our population of LOPD patients appears generally more clinically severe at baseline, so it will be 
interesting at the end of the study to see if we can see beneficial results of exercise even in more 
severely affected patients. Moreover, this is the first time that the effect of hyperproteic diet 
associated to exercise is evaluated in a cohort of patients already long term treated with ERT. 
Late onset Pompe disease in advanced stages causes significant disability with great impact for the 
health care system. At present, ERT with human recombinant alfa-glucosidase is the only available 
treatment for LOPD, but its effectiveness seems to be limited and a dosage augmentation is not 
feasible because of its high costs. Exercise training and diet therapy could be helpful in increasing 
ERT clinical efficacy, improving patients' muscle function, reducing their disability, and 
ameliorating their quality of life. These effects may result in a reduction of patients' demand of 
assistance and in a lower cost for the health system. 
 
Conclusions 
Our preliminary data suggest a beneficial effect of exercise training performed at home in patients 
with late onset Pompe disease on chronic ERT. However, we should attend the end of the study to 
perform statistical analysis and draw proper conclusions.  
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CONCLUDING REMARKS 
 
Our studies, focused on late onset Pompe disease, improve the current knowledge on clinical long 
term outcome of patients under enzyme replacement therapy (ERT), confirm the utility of 
functional evaluation of exercise tolerance in patients’ follow up, and propose dietetic and physical 
activity interventions as addictive therapy to improve the effects of the ERT. 
 
In particular we have observed: 
 
1) after 5 years of regular treatment with ERT, patients with the juvenile form of Pompe 
disease show an improvement or even a normalization (for those who were diagnosed in an 
asymptomatic phase) of muscle enzymes, and stabilize motor and respiratory functions.  
Patients who started therapy in an asymptomatic phase are still free of symptoms after 6 
years of follow up. 
Although these findings should be confirmed by studies conducted on larger cohorts, our 
results confirm the hypothesis that the ERT is more efficient if started at early stages of the 
disease. 
 
2) Functional evaluation of exercise tolerance on a cycle-ergometer is a safe and useful toll to 
assess clinical outcome of LOPD patients, which can be used also in patients with walking 
difficulties and patients with mild or moderate respiratory insufficiency. The peripheral 
muscle component is prominent in determining the VO2 peak decrease, rather than the 
respiratory component in LOPD patients.  
ERT do not have an acute effect on this test, so it can be performed regardless the ERT 
timing.  
Compared to the standard and widely used six minutes walking test, exercise tolerance test 
on a cycle-ergometer seems to be more sensible in detecting exercise intolerance in LOPD 
patients, thus we suggest to use it especially in the long term follow up of patients with mild 
form of the disease, to detect early changes. 
Patients who regularly perform physical activity show better performances at the exercise 
tolerance test, regardless the severity of the disease, confirming the potential beneficial 
effect of prescribing exercise in LOPD patients. 
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3) Although only preliminary results are available, a personalized aerobic exercise training 
performed at home seems to ameliorate skeletal muscle force, maximal aerobic capacity and 
peripheral muscle oxygen extraction in LOPD patients chronically treated with ERT. 
Adherence to diet therapy seems more difficult than compliance with exercise training. 
Interesting results are waited by the end of this study. 
 
In the present thesis the functional evaluation of exercise tolerance was utilized as a new instrument 
to clinically evaluate LOPD patients’ outcome. The reported studies, in particular study II e III, can 
be considered an example of translational medicine, in which methods and procedures developed at 
a research level are applied to patients with the aim to improve their follow up and treatment. 
Moreover, these studies can be considered as a model for utilizing exercise functional tests in the 
assessment of different neuromuscular disorders in future studies. 
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